Document:

EX-10.1

 Exhibit 10.1 

Execution Version 

1LIFE HEALTHCARE, INC. 

AMENDED AND RESTATED 

INVESTOR RIGHTS AGREEMENT 

 TABLE OF CONTENTS 

 

							
	 	 	 	  	 PAGE
	 
	 SECTION 1.
	 	 GENERAL
	  	 	1	 
			
	 1.1
	 	 Amendment and Restatement of Prior Agreement
	  	 	1	 
			
	 1.2
	 	 Definitions
	  	 	2	 
			
	 SECTION 2.
	 	 RESTRICTIONS ON TRANSFER; REGISTRATION
	  	 	4	 
			
	 2.1
	 	 Restrictions on Transfer
	  	 	4	 
			
	 2.2
	 	 Demand Registration
	  	 	6	 
			
	 2.3
	 	 Piggyback Registrations
	  	 	7	 
			
	 2.4
	 	 Form S-3 Registration; Underwritten Shelf
Takedowns
	  	 	8	 
			
	 2.5
	 	 Expenses of Registration
	  	 	11	 
			
	 2.6
	 	 Obligations of the Company
	  	 	12	 
			
	 2.7
	 	 Delay of Registration; Furnishing Information
	  	 	15	 
			
	 2.8
	 	 Indemnification
	  	 	15	 
			
	 2.9
	 	 Assignment of Registration Rights
	  	 	17	 
			
	 2.10
	 	 Limitation on Subsequent Registration Rights
	  	 	18	 
			
	 2.11
	 	 “Market Stand-Off” Agreement
	  	 	18	 
			
	 2.12
	 	 Agreement to Furnish Information
	  	 	18	 
			
	 2.13
	 	 Rule 144 Reporting
	  	 	19	 
			
	 2.14
	 	 Termination
	  	 	19	 
			
	 SECTION 3.
	 	 COVENANTS OF THE COMPANY
	  	 	19	 
			
	 3.1
	 	 Basic Financial Information
	  	 	19	 
			
	 3.2
	 	 Inspection Rights
	  	 	20	 
			
	 3.3
	 	 Confidentiality of Records
	  	 	20	 
			
	 3.4
	 	 Stock Vesting
	  	 	21	 
			
	 3.5
	 	 Qualified Small Business Stock
	  	 	21	 
			
	 3.6
	 	 Proprietary Information and Inventions Agreements
	  	 	21	 
			
	 3.7
	 	 Termination of Covenants
	  	 	21	 
			
	 SECTION 4.
	 	 RIGHTS OF FIRST REFUSAL
	  	 	22	 
			
	 4.1
	 	 Subsequent Offerings
	  	 	22	 
			
	 4.2
	 	 Exercise of Rights
	  	 	22	 
			
	 4.3
	 	 Issuance of Equity Securities to Other Persons
	  	 	22	 
			
	 4.4
	 	 Sale Without Notice
	  	 	23	 
			
	 4.5
	 	 Termination and Waiver of Rights of First Refusal
	  	 	23	 
			
	 4.6
	 	 Assignment of Rights of First Refusal
	  	 	23	 
			
	 4.7
	 	 Excluded Securities
	  	 	23	 

  
 i 

 TABLE OF CONTENTS 

(CONTINUED) 
  

							
	 	 	 	  	PAGE	 
	 SECTION 5.
	 	 MISCELLANEOUS
	  	 	23	 
			
	 5.1
	 	 Governing Law
	  	 	23	 
			
	 5.2
	 	 Successors and Assigns
	  	 	23	 
			
	 5.3
	 	 Entire Agreement
	  	 	24	 
			
	 5.4
	 	 Severability
	  	 	24	 
			
	 5.5
	 	 Amendment and Waiver
	  	 	24	 
			
	 5.6
	 	 Delays or Omissions
	  	 	24	 
			
	 5.7
	 	 Notices
	  	 	25	 
			
	 5.8
	 	 Attorneys’ Fees
	  	 	25	 
			
	 5.9
	 	 Titles and Subtitles
	  	 	25	 
			
	 5.10
	 	 Additional Investors
	  	 	25	 
			
	 5.11
	 	 Counterparts
	  	 	25	 
			
	 5.12
	 	 Aggregation of Stock
	  	 	25	 
			
	 5.13
	 	 Pronouns
	  	 	25	 

  
 ii 

 1LIFE HEALTHCARE, INC. 

AMENDED AND RESTATED 

INVESTOR RIGHTS AGREEMENT 

THIS AMENDED AND RESTATED INVESTOR RIGHTS
AGREEMENT (the “Agreement”) is entered into as of the 15 day of January, 2020, by and among 1LIFE HEALTHCARE, INC., a Delaware corporation (the
“Company”), and the investors listed on Exhibit A hereto, referred to hereinafter as the “Investors” and each individually as an “Investor.” 

RECITALS 

WHEREAS, certain of the Investors purchased shares of the Company’s Series I Preferred Stock (the
“Series I Stock”) pursuant to that certain Series I Preferred Stock Purchase Agreement (the “Purchase Agreement”) dated as of August 21, 2018; 

WHEREAS, the obligations in the Purchase Agreement are conditioned upon the execution and delivery of this Agreement;

 WHEREAS, certain of the Investors (the “Prior Investors”) are holders of the Company’s
Series A Preferred Stock (the “Series A Stock”), Series B Preferred Stock (the “Series B Stock”), Series C Preferred Stock (the “Series C Stock”), Series D Preferred Stock
(the “Series D Stock”), Series E Preferred Stock (the “Series E Stock”), Series F Preferred Stock (the “Series F Stock”), Series G Preferred Stock (the “Series G Stock”) and Series
H Preferred Stock (the “Series H Stock” and together with the Series A Stock, Series B Stock, Series C Stock, Series D Stock, Series E Stock, Series F Stock, Series G Stock and Series I Stock, the “Preferred
Stock”); 
 WHEREAS, the Prior Investors and the Company are parties to an Amended and Restated Investor
Rights Agreement dated August 21, 2018 (the “Prior Agreement”); 

WHEREAS, the parties to the Prior Agreement desire to amend and restate the Prior Agreement
and accept the rights and covenants hereof in lieu of their rights and covenants under the Prior Agreement; and 

WHEREAS, pursuant to Section 5.5 of the Prior Agreement, such agreement may only be modified as set
forth herein by way of a written instrument signed by the Company and certain of the undersigned Investors, which this Agreement constitutes; and 

WHEREAS, in anticipation of the proposed initial public offering of the Company, the Company and the Investors have
agreed to the registration rights, information rights, and other rights as set forth below. 
 NOW,
THEREFORE, in consideration of these premises and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto agree as follows: 

SECTION 1. GENERAL. 

1.1    Amendment and Restatement of Prior Agreement. The Prior Agreement is hereby amended in its entirety and
restated herein. Such amendment and restatement is effective upon the execution of this Agreement by the Company and the holders a majority of the Registrable Securities held 

 
by the Prior Investors outstanding as of the date of this Agreement. Upon such execution, all provisions of, rights granted and covenants made in the Prior Agreement are hereby waived, released
and superseded in their entirety and shall have no further force or effect, including, without limitation, all rights of first refusal set forth in Section 4 and any notice period associated therewith otherwise applicable to the transactions
contemplated by the Purchase Agreement. 
 1.2    Definitions. As used in this Agreement the following terms
shall have the following respective meanings: 
 (a)    “Affiliate” of any Person means a
Person that directly or indirectly, through one or more intermediaries, controls, is controlled by or is under common control with the first mentioned Person, including without limitation any general partner, managing member, officer or director of
such Person or any venture capital fund now or hereafter existing that is controlled by one or more general partners or managing members of, or shares the same management company with, such Person or any investment fund, managed account vehicle,
collective investment scheme or comparable investment vehicle (“Fund”) now or hereafter existing that shares the same management company or registered investment advisor with such Person or any Fund now or hereafter existing that is
controlled by, under common control with, managed or advised by the same management company or registered investment advisor that controls, is under common control with, manages or advises the Fund that controls such Person. A Person shall be deemed
to control another Person if such first Person possesses directly or indirectly the power to direct, or cause the direction of, the management and policies of the second Person, whether through the ownership of voting securities, by contract or
otherwise. 
 (b)    “Business Day” means any day other than a Saturday, Sunday or other day on
which commercial banks in New York City are authorized or required by applicable law or executive order to close. 

(c)    “Exchange Act” means the Securities Exchange Act of 1934, as amended. 

(d)    “Form S-3” means such form under the
Securities Act as in effect on the date hereof or any successor or similar registration form under the Securities Act subsequently adopted by the SEC which permits inclusion or incorporation of substantial information by reference to other documents
filed by the Company with the SEC. 
 (e)    “Holder” means any person owning of
record Registrable Securities that have not been sold to the public or any assignee of record of such Registrable Securities in accordance with Section 2.9 hereof. 

(f)    “Initial Offering” means the Company’s first firm commitment
underwritten public offering of its Common Stock Registered under the Securities Act. 

(g)    “Person” means an individual or group of individuals, a corporation, an association, a
limited or general partnership, a limited liability company, an estate, a trust, and any other entity or organization, governmental or otherwise. 

(h)    “Register,” “registered,” and “registration”
refer to a registration effected by preparing and filing a registration statement in compliance with the Securities Act, and the declaration or ordering of effectiveness of such registration statement or document. 

(i)    “Registrable Securities” means (a) Common Stock of the Company issuable
or issued upon conversion of the Shares; (b) any Common Stock of the Company issued as (or issuable upon 

  
 2 

 
the conversion or exercise of any warrant, right or other security which is issued as) a dividend or other distribution with respect to, or in exchange for or in replacement of, such
above-described securities; (c) any equity securities issued or issuable with respect to the Shares described in clauses (a) or (b) above by way of combination of stock or shares, recapitalization, merger, consolidation or other
reorganization and, for purposes of Sections 2.3, 2.4, 2.5, 2.6, 2.7, 2.8, 2.11, 2.12 and 2.13 only; and (d) shares of Common Stock issued or issuable upon conversion of the Series C Stock, Series D Stock, Series E Stock and Series G Stock
issued or issuable upon exercise of the Warrants. Notwithstanding the foregoing, Registrable Securities shall not include any securities (i) sold by a person to the public either pursuant to a registration statement or Rule 144, (ii) sold in a
private transaction in which the transferor’s rights under Section 2 of this Agreement are not assigned or (iii) held by a Holder (together with its Affiliates) if the Company has completed its Initial Offering and all shares of
Common Stock of the Company issuable or issued upon conversion of the Shares held by and issuable to such Holder (and its Affiliates) can be immediately sold without registration in compliance with Rule 144 during any ninety (90) day period.

 (j)    “Registrable Securities then outstanding” shall be the number of shares
of the Company’s Common Stock that are Registrable Securities and either (a) are then issued and outstanding or (b) are issuable pursuant to then exercisable, convertible and/or exchangeable securities. 

(k)    “Registration Expenses” shall mean all expenses incurred by the Company in
complying with Sections 2.2, 2.3 and 2.4 hereof, including, without limitation, all registration and filing fees, printing expenses, escrow fees, fees and disbursements of counsel for the Company, reasonable fees and disbursements of a single
special counsel for the Holders, blue sky fees and expenses and the expense of any regular or special audits incident to or required by any such registration (but excluding the compensation of regular employees of the Company which shall be paid in
any event by the Company, underwriting discounts and commissions, stock transfer taxes, and fees of accountants for the Holders and additional counsel to the Holders). 

(l)    “SEC” or “Commission” means the Securities and Exchange
Commission. 
 (m)    “Securities Act” shall mean the Securities Act of 1933, as
amended. 
 (n)    “Selling Expenses” shall mean all underwriting discounts and
selling commissions applicable to the sale. 
 (o)    “Shares” shall mean the
shares of the Company’s Series I Stock issued pursuant to the Purchase Agreement (or in connection with the transactions contemplated thereby) and shares of the Company’s Series A Stock, Series B Stock, Series C Stock, Series D Stock,
Series E Stock, Series F Stock, Series G Stock and Series H Stock held from time to time by the Investors listed on Exhibit A hereto and their permitted assigns. 

(p)    “Special Registration Statement” shall mean (i) a registration statement relating to
any employee benefit plan or (ii) with respect to any corporate reorganization or transaction under Rule 145 of the Securities Act, any registration statements related to the issuance or resale of securities issued in such a transaction or
(iii) a registration related to stock issued upon conversion of debt securities. 

(q)    “Warrants” shall mean (i) those certain warrants held by Silicon Valley Bank
(A) dated February 26, 2010 to purchase shares of Series C Stock, (B) dated June 28, 2011 to purchase shares of Series D Stock, (C) dated January 29, 2013 to purchase shares of Series E Stock, and (D) dated
January 26, 2015 to purchase shares of Series G Stock; (ii) that certain warrant to purchase shares of Series G Stock held by Benchmark Capital Partners V, L.P. dated October 3, 2015; (iii) that certain warrant to purchase shares of
Series G Stock held by Oak Investment Partners XII, Limited Partnership dated October 5, 2015; 

  
 3 

 
(iv) that certain warrant to purchase shares of Series G Stock held by Maverick Holdings L, LLC dated October 7, 2015; (v) that certain warrant to purchase shares of Series G Stock held by
GV 2013, L.P. dated December 5, 2015; (vi) that certain warrant to purchase shares of Series G Stock held by DAG Ventures IV, L.P. dated October 12, 2015; (vii) that certain warrant to purchase shares of Series G Stock held by DAG Ventures
IV-QP, L.P. dated October 12, 2015; (viii) that certain warrant to purchase shares of Series G Stock held by Redmile Capital Offshore Fund II, Ltd. dated October 14, 2015; (ix) that certain warrant
to purchase shares of Series G Stock held by Redmile Private Investments I, LP dated October 14, 2015; (x) that certain warrant to purchase shares of Series G Stock held by Redmile Private Investments I Affiliates, LP dated October 14,
2015; (xi) that certain warrant to purchase shares of Series G Stock held by Allen Partners Fund I LP dated October 28, 2015; (xii) that certain warrant to purchase shares of Series G Stock held by Robert Lowe dated October 28, 2015;
(xiii) that certain warrant to purchase shares of Series G Stock held by John Koski dated October 28, 2015; (xiv) that certain warrant to purchase shares of Series G Stock held by Dignity Health dated November 4, 2015; and (xv) that
certain warrant to purchase shares of Series G Stock held by Redmile Strategic Master Fund, LP, a Cayman Island limited partnership dated December 1, 2017. 

SECTION 2. RESTRICTIONS ON TRANSFER; REGISTRATION. 

2.1    Restrictions on Transfer. 

(a)    Each Holder agrees not to make any sale, assignment, transfer, pledge or other disposition of all or any
portion of the Shares or Registrable Securities, or any beneficial interest therein, unless and until: 

(i)    there is then in effect a registration statement under the Securities Act covering such proposed
disposition and such disposition is made in accordance with such registration statement; or 

(ii)    (A) The Holder has complied with all of the provisions of this Agreement and that certain Right of
First Refusal and Co-Sale Agreement by and between the parties and dated as of the date hereof, (B) transferee has agreed in writing for the benefit of the Company to take and hold such Shares or
Registrable Securities subject to, and to be bound by, the terms of this Agreement, (C) such Holder shall have notified the Company of the proposed disposition and shall have furnished the Company with a detailed statement of the circumstances
surrounding the proposed disposition, and (D) if reasonably requested by the Company, such Holder shall have furnished the Company with an opinion of counsel, reasonably satisfactory to the Company, that such disposition will not require
registration of such shares under the Securities Act. It is agreed that the Company will not require opinions of counsel for transactions made pursuant to Rule 144, except in unusual circumstances, or for transfers to Affiliated entities. After its
Initial Offering, the Company will not require any transferee pursuant to Rule 144 to be bound by the terms of this Agreement or a statement of the circumstances surrounding the proposed disposition if the shares so transferred do not remain
Registrable Securities hereunder following such transfer. 
 (b)    Notwithstanding the provisions of subsection
(a) above: 
 (i)    no such restriction shall apply to a transfer by a Holder that is (A) a
partnership transferring to its partners or former partners in accordance with partnership interests or to the estate of any such partner or former partner or the transfer by gift, will or intestate succession of any partner to his or her spouse or
to the siblings, lineal descendants or ancestors of such partner or his or her spouse, (B) a corporation transferring to a wholly-owned subsidiary or a parent corporation that owns all of the capital stock of the Holder, (C) a limited
liability company transferring to its members or former members in accordance with their interest in the limited liability company, (D) an individual transferring to the 

  
 4 

 
Holder’s immediate family member or trust for the benefit of an individual Holder, (E) to an Affiliate or (F) to the Company or another Holder; provided that in each case
the transferee will agree in writing to be subject (to the extent not already subject) to the terms of this Agreement to the same extent as if he or she were an original Holder hereunder; and 

(ii)    After the third anniversary of the Closing (as defined in the Purchase Agreement), Carlyle Partners VII
Holdings, L.P. (“Carlyle”) shall be entitled to sell or otherwise transfer all or part of its Shares or Registrable Securities to one or more unaffiliated third parties, provided that such transferee will agree in writing to be
subject (to the extent not already subject) to the terms of this Agreement to the same extent as if he, she or it were an original Holder hereunder. 

(c)    Each certificate representing Shares or Registrable Securities shall (unless otherwise permitted by the
terms of this Agreement) be stamped or otherwise imprinted with legends substantially similar to the following (in addition to any legend required under applicable state securities laws): 

THE SECURITIES REPRESENTED HEREBY HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933 (THE “ACT”), OR UNDER THE
SECURITIES LAWS OF CERTAIN STATES AND MAY NOT BE OFFERED, SOLD OR OTHERWISE TRANSFERRED, ASSIGNED, PLEDGED OR HYPOTHECATED EXCEPT AS PERMITTED UNDER THE ACT AND APPLICABLE STATE SECURITIES LAWS PURSUANT TO REGISTRATION OR AN EXEMPTION THEREFROM. THE
COMPANY MAY REQUIRE AN OPINION OF COUNSEL SATISFACTORY TO THE COMPANY AND ITS COUNSEL THAT SUCH OFFER, SALE OR TRANSFER, PLEDGE OR HYPOTHECATION OTHERWISE COMPLIES WITH THE ACT AND ANY APPLICABLE STATE SECURITIES LAWS. 

THE SALE, PLEDGE, HYPOTHECATION OR TRANSFER OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE IS SUBJECT TO THE TERMS AND CONDITIONS OF A
CERTAIN INVESTOR RIGHTS AGREEMENT BY AND BETWEEN THE STOCKHOLDER AND THE COMPANY. COPIES OF SUCH AGREEMENT MAY BE OBTAINED UPON WRITTEN REQUEST TO THE SECRETARY OF THE COMPANY. 

(d)    The Company shall be obligated to reissue promptly unlegended certificates at the request of any Holder
thereof if the Company has completed its Initial Offering and the Holder shall have obtained an opinion of counsel (which counsel may be counsel to the Company) reasonably acceptable to the Company to the effect that the securities proposed to be
disposed of may lawfully be so disposed of without registration, qualification and legend, provided that the second legend listed above shall be removed only at such time as the Holder of such certificate is no longer subject to any
restrictions hereunder (except that the Company shall not require an opinion of counsel in connection with transfers to Affiliated entities or pursuant to Rule 144). 

  
 5 

 (e)    Any legend endorsed on an instrument pursuant to
applicable state securities laws and the stop-transfer instructions with respect to such securities shall be removed upon receipt by the Company of an order of the appropriate blue sky authority authorizing such removal. 

2.2    Demand Registration. 

(a)    Subject to the conditions of this Section 2.2, if the Company shall receive a written request from
(x) beginning on the earlier of (i) five (5) years after the date of this Agreement and (ii) six (6) months after the Company’s Initial Offering, the Holders of at least sixty-five percent (65%) of the Registrable Securities then
outstanding (the “Preferred Initiating Holders”) or (y) beginning six (6) months after the Company’s Initial Offering, Carlyle or any of its Affiliates holding Registrable Securities (the “Carlyle Initiating
Holders” and, together with the Preferred Initiating Holders, the “Initiating Holders”), in each case, that the Company file a registration statement under the Securities Act for an underwritten public offering with an
anticipated aggregate offering price in excess of $50,000,000, then the Company shall, within thirty (30) days of the receipt thereof, give written notice of such request to all Holders, and subject to the limitations of this Section 2.2,
effect, as expeditiously as reasonably possible, the registration under the Securities Act of all Registrable Securities that all Holders request to be registered. 

(b)    All Holders proposing to distribute their securities pursuant to a registration under this Section 2.2
shall enter into an underwriting agreement in customary form with the underwriter or underwriters selected for such underwriting by (i) the Holders of a majority of the Registrable Securities held by all Preferred Initiating Holders or
(ii) the Carlyle Initiating Holders, as applicable (which underwriter or underwriters, in each case, shall be reasonably acceptable to the Company). The right of any Holder to include its Registrable Securities shall be conditioned upon such
Holder’s participation in such underwriting and the inclusion of such Holder’s Registrable Securities in the underwriting to the extent provided herein (unless otherwise mutually agreed by such Holder and (x) the Holders of a majority
of the Registrable Securities held by all Preferred Initiating Holders or (y) the Carlyle Initiating Holders, as applicable, with respect to such participation and inclusion). If a person who has requested inclusion in such registration as
provided in Section 2.2(a) does not agree to the terms of any such underwriting, such person shall be excluded therefrom by written notice from the Company, the underwriter or the applicable Initiating Holders. Notwithstanding any other
provision of this Section 2.2 or Section 2.4, if the underwriter advises the Company that marketing factors require a limitation of the number of securities to be underwritten (including Registrable Securities) then the Company shall so
advise all Holders of Registrable Securities that would otherwise be underwritten pursuant hereto, and (A) in the case of a registration requested by the Preferred Initiating Holders, the number of shares that may be included in the
underwriting shall be allocated to the Holders of such Registrable Securities on a pro rata basis based on the number of Registrable Securities held by all such Holders (including the Initiating Holders) or in such other proportion as shall
be agreed by all holders of Registrable Securities participating in the underwriting and (B) in the case of a registration requested by the Carlyle Initiating Holders, the number of shares that may be included in the underwriting shall be
allocated first to the Carlyle Initiating Holders and then to the Holders of such Registrable Securities on a pro rata basis based on the number of Registrable Securities held by all such Holders (excluding the Carlyle Initiating Holders) or
in such other proportion as shall be agreed by the Carlyle Initiating Holders and all other holders of Registrable Securities participating in the underwriting; provided, however, that the number of shares of Registrable
Securities to be included in such underwriting and registration shall not be reduced unless all other securities of the Company not included in the request by the Initiating Holders are first entirely excluded from the underwriting and registration.
Any Registrable Securities excluded or withdrawn from such underwriting shall be withdrawn from the registration. For purposes of the provision in this Section 2.2(b) concerning apportionment as it relates to demand registrations under
Section 2.2 or Underwritten Shelf Takedowns under Section 2.4, for any Holder that is a partnership, limited liability company, or corporation, the partners, retired partners, members, retired members, stockholders, and Affiliates of such
Holder, or the estates and immediate family members of any 

  
 6 

 
such partners, retired partners, members, and retired members and any trusts for the benefit of any of the foregoing Persons, shall be deemed to be a single “Holder”, and any pro
rata reduction with respect to such “Holder” shall be based upon the aggregate number of Registrable Securities owned by all Persons included in such “Holder”, as defined in this sentence. 

(c)    The Company shall not be required to effect a registration pursuant to this Section 2.2: 

(i)    after the Company has effected (x) two (2) registrations pursuant to this Section 2.2 at the
request of the Preferred Initiating Holders and (y) two (2) registrations pursuant to this Section 2.2 at the request of the Carlyle Initiating Holders, and such registrations have been declared or ordered effective and pursuant to which
securities have been sold (other than if the Holders elected not to sell securities pursuant to such registration); 

(ii)    during the period starting with the date of filing of, and ending on the date one hundred eighty
(180) days following the effective date of a registration statement pertaining to a public offering subject to Section 2.3, other than pursuant to a Special Registration Statement; provided that the Company makes reasonable good
faith efforts to cause such registration statement to become effective; 
 (iii)    if within fifteen
(15) days of receipt of a written request from Initiating Holders pursuant to Section 2.2(a), the Company gives notice to the Holders of the Company’s intention to file a registration statement for a public offering subject to
Section 2.3, other than pursuant to a Special Registration Statement, within sixty (60) days of the Company’s giving such notice; provided that the Company makes reasonable good faith efforts to cause such registration
statement to become effective; 
 (iv)    if the Company shall furnish to Holders requesting a registration
statement pursuant to this Section 2.2 a certificate signed by the Chairman of the Board stating that, in the good faith judgment of the Board of Directors of the Company, it would be seriously detrimental to the Company and its stockholders
for such registration statement to be effected at such time, in which event the Company shall have the right to defer such filing for a period of not more than one hundred twenty (120) days after receipt of the request of the Initiating
Holders; provided that such right to delay a request shall be exercised by the Company not more than once in any twelve (12) month period; and provided, further that the Company shall not register any
securities for the account of itself or any other stockholder during such one hundred twenty (120) day period (other than pursuant to a Special Registration Statement); 

(v)    if the Initiating Holders propose to dispose of shares of Registrable Securities that may be immediately
registered on Form S-3 or that have been included on a registration statement on Form S-3, including pursuant to a request made pursuant to Section 2.4 below;
or 
 (vi)    in any particular jurisdiction in which the Company would be required to qualify to do business or
to execute a general consent to service of process in effecting such registration, qualification or compliance. 

2.3    Piggyback Registrations. The Company shall notify all Holders of Registrable Securities in writing at
least fifteen (15) days prior to the filing of any registration statement under the Securities Act for purposes of a public offering of securities of the Company (including, but not limited to, registration statements relating to
secondary offerings of securities of the Company, but excluding Special Registration Statements and registration in connection with any consolidation, merger, or reorganization, or with any employee benefit plan) and will afford each such Holder an
opportunity to include in such registration statement all or part of such Registrable Securities held by such Holder. Each Holder desiring to include in any such registration statement all or any part of the Registrable Securities held by it shall,
within fifteen 

  
 7 

 
(15) days after the above-described notice from the Company, so notify the Company in writing. If a Holder decides not to include all of its Registrable Securities in any registration statement
thereafter filed by the Company, such Holder shall nevertheless continue to have the right to include any Registrable Securities in any subsequent registration statement or registration statements as may be filed by the Company with respect to
offerings of its securities, all upon the terms and conditions set forth herein. 
 (a)    Underwriting.
If the registration statement of which the Company gives notice under this Section 2.3 is for an underwritten offering, the Company shall so advise the Holders of Registrable Securities. In such event, the right of any such Holder to
include Registrable Securities in a registration pursuant to this Section 2.3 shall be conditioned upon such Holder’s participation in such underwriting and the inclusion of such Holder’s Registrable Securities in the underwriting to
the extent provided herein. All Holders proposing to distribute their Registrable Securities through such underwriting shall enter into an underwriting agreement in customary form with the underwriter or underwriters selected for such underwriting
by the Company. Notwithstanding any other provision of this Agreement, the Company and the underwriter may in their discretion limit the number of shares to be underwritten, in which case the number of shares to be underwritten shall be allocated
first to the Company and then to the Holders on a pro rata basis based on the total number of Registrable Securities held by the Holders; provided, however, that no such reduction shall reduce the amount of securities of the
selling Holders included in the registration below twenty-five percent (25%) of the total amount of securities included in such registration, unless such offering is the Initial Offering and such registration does not include shares of any other
selling stockholder, in which event any or all of the Registrable Securities of the Holders may be excluded in accordance with the immediately preceding clause. In no event will shares of any other selling stockholder be included in such
registration that would reduce the number of shares which may be included by Holders without the written consent of Holders of a majority of the Registrable Securities proposed to be sold in the offering. If any Holder disapproves of the terms of
any such underwriting, such Holder may elect to withdraw therefrom by written notice to the Company and the underwriter, delivered at least ten (10) business days prior to the effective date of the registration statement. Any Registrable
Securities excluded or withdrawn from such underwriting shall be excluded and withdrawn from the registration. For any Holder which is a partnership, limited liability company or corporation, Affiliates of such Holder, partners, retired partners,
members, retired members and stockholders of such Holder, or the estates and family members of any such partners, retired partners, members and retired members and any trusts for the benefit of any of the foregoing Persons shall be deemed to be a
single “Holder,” and any pro rata reduction with respect to such “Holder” shall be based upon the aggregate amount of shares carrying registration rights owned by all Persons included in such “Holder,” as defined
in this sentence. 
 (b)    Right to Terminate Registration. The Company shall have the right to terminate
or withdraw any registration initiated by it under this Section 2.3 whether or not any Holder has elected to include securities in such registration. The Registration Expenses of such withdrawn registration shall be borne by the Company in
accordance with Section 2.5 hereof. 
 2.4    Form S-3 Registration;
Underwritten Shelf Takedowns. In case the Company shall receive from any Holder of Registrable Securities a written request or requests that the Company effect a registration on Form S-3 (or any
successor to Form S-3) or any similar short-form registration statement pursuant to Rule 415 under the Securities Act (each a “Shelf Registration Statement”) and any related qualification
or compliance with respect to all or a part of the Registrable Securities owned by such Holder or Holders, the Company will: 

(a)    promptly give written notice of the proposed registration, and any related qualification or compliance, to
all other Holders of Registrable Securities; and 

  
 8 

 (b)    as soon as practicable, effect such registration and all
such qualifications and compliances as may be so requested and as would permit or facilitate the sale and distribution of all or such portion of such Holder’s or Holders’ Registrable Securities as are specified in such request, together
with all or such portion of the Registrable Securities of any other Holder or Holders joining in such request as are specified in a written request given within fifteen (15) days after receipt of such written notice from the Company;
provided, however, that the Company shall not be obligated to effect any such registration, qualification or compliance pursuant to this Section 2.4: 

(i)    after the Company has filed two (2) Shelf Registration Statements pursuant to this Section 2.4
within the twelve (12) month period preceding the date of such request, and such registrations have been declared or ordered effective or became effective upon filing; 

(ii)    if Form S-3 is not available for such offering by the
Holders; 
 (iii)    if the Holders, together with the holders of any other securities of the Company entitled
to inclusion in such registration, propose to sell Registrable Securities and such other securities (if any) at an aggregate price to the public of less than five million dollars ($5,000,000); 

(iv)    if within fifteen (15) days of receipt of a written request from any Holder or Holders pursuant to
this Section 2.4, the Company gives notice to such Holder or Holders of the Company’s intention to make a public offering within sixty (60) days, other than pursuant to a Special Registration Statement; provided that the
Company makes reasonable good faith efforts to cause such registration statement to become effective; 

(v)    if the Company shall furnish to the Holders a certificate signed by the Chairman of the Board of Directors
of the Company stating that in the good faith judgment of the Board of Directors of the Company, it would be seriously detrimental to the Company and its stockholders for such Shelf Registration Statement to be effected at such time, in which event
the Company shall have the right to defer the filing of the Shelf Registration Statement for a period of not more than one hundred twenty (120) days after receipt of the request of the Holder or Holders under this Section 2.4;
provided that such right to delay a request shall be exercised by the Company not more than once in any twelve (12) month period; provided, further, that the Company shall not register any securities for the
account of itself or any other stockholder during such one hundred twenty (120) day period (other than pursuant to a Special Registration Statement); or 

(vi)    in any particular jurisdiction in which the Company would be required to qualify to do business or to
execute a general consent to service of process in effecting such registration, qualification or compliance. 

(c)    Subject to the foregoing, the Company shall file a Shelf Registration Statement covering the Registrable
Securities and other securities so requested to be registered as soon as practicable after receipt of the requests of the Holders. Registrations effected pursuant to this Section 2.4 shall not be counted as demands for registration or
registrations effected pursuant to Section 2.2. 
 (d)    At any time during which a Shelf Registration
Statement on Form S-3 is effective under the Securities Act (or, in the event that the Company is a WKSI (as defined below), at any time that a Shelf Registration Statement that will be automatically effective
upon filing is requested in accordance with Section 2.4), the Preferred Initiating Holders or Carlyle Initiating Holders with Registrable Securities included on such Shelf Registration Statement on Form
S-3 may request to sell all or any portion of their Registrable Securities in an underwritten offering that is registered pursuant to the Shelf Registration 

  
 9 

 
Statement on Form S-3 (each, an “Underwritten Shelf Takedown”). All requests by Holders for Underwritten Shelf Takedowns shall be made by
giving written notice to the Company (the “Demand Shelf Takedown Notice”), which notice shall specify the approximate number of Registrable Securities proposed to be sold in the Underwritten Shelf Takedown and whether such offering
will be a non-marketed block trade. Within ten (10) Business Days after receipt of any Demand Shelf Takedown Notice (or two (2) Business days in the event the Demand Shelf Takedown Notice requests a non-marketed block trade), the Company shall give written notice of such requested Underwritten Shelf Takedown to all other Holders which have Registrable Securities included on such Shelf Registration Statement on
Form S-3 (the “Company Shelf Takedown Notice”) and, subject to the provisions of Section 2.4(f) below, shall include in such Underwritten Shelf Takedown all Registrable Securities with
respect to which the Company has received written requests for inclusion therein (which requests shall be revocable only with the consent of Carlyle or, if Carlyle is not participating in such Underwritten Shelf Takedown, by the Holders of a
majority of the Registrable Securities held by all Preferred Initiating Holders) within five (5) Business Days after sending the Company Shelf Takedown Notice (or such earlier time at which all Holders that have Registrable Securities included
on such Shelf Registration Statement have provided responses to the Company Shelf Takedown Notice). So long as a Shelf Registration Statement is effective, no Holder may request any demand registration pursuant to Section 2.2 with respect to
Registrable Securities that are registered or registrable on such Shelf Registration Statement. Subject to the provisions of Section 2.4(f) below, the Preferred Initiating Holders and the Carlyle Initiating Holders shall be entitled to an
unlimited number of Underwritten Shelf Takedowns; provided, however, that each Underwritten Shelf Takedown shall count against the number of demand registrations for purposes of the Company’s obligation pursuant to Section 2.2(c)(i)
to effect no more than (x) two (2) demand registrations at the request of the Preferred Initiating Holders and (y) two (2) demand registrations at the request of the Carlyle Initiating Holders. 

(e)    All Holders proposing to include their Registrable Securities in an Underwritten Shelf Takedown shall enter
into an underwriting agreement in customary form with the underwriter or underwriters selected for such underwriting by Carlyle or, if Carlyle is not participating in such Underwritten Shelf Takedown, by the Holders of a majority of the Registrable
Securities held by all Preferred Initiating Holders (which underwriter or underwriters, in each case, shall be reasonably acceptable to the Company). The right of any Holder to include its Registrable Securities shall be conditioned upon such
Holder’s participation in such underwriting on the terms and conditions (including with respect to the price at which the Registrable Securities included therein will be sold to the underwriter or underwriters) as agreed upon by Carlyle or, if
Carlyle is not participating in such Underwritten Shelf Takedown, by the Holders of a majority of the Registrable Securities held by all Preferred Initiating Holders, and the underwriter or underwriters of such underwriting (unless otherwise
mutually agreed by such Holder and Carlyle or, if Carlyle is not participating in such Underwritten Shelf Takedown, the Holders of a majority of the Registrable Securities held by all Preferred Initiating Holders with respect to such participation
and inclusion). If a person who has requested inclusion in such Underwritten Shelf Takedown as provided in Section 2.4(d) does not agree to the terms of any such underwriting, such person shall be excluded therefrom by written notice from the
Company, the underwriter(s) or the Preferred Initiating Holders or the Carlyle Initiating Holders, as applicable. 

(f)    The Company shall not be obligated to effect any Underwritten Shelf Takedown pursuant to this
Section 2.4: 
 (i)    after the Company has effected two (2) Underwritten Shelf Takedowns within the
twelve (12) month period preceding the date of the prospectus supplement proposed to be filed with the Commission pursuant to Rule 424(b) under the Securities Act for the Underwritten Shelf Takedown; 

  
 10 

 (ii)    within ninety (90) days of the date of the
prospectus supplement filed with the Commission pursuant to Rule 424(b) under the Securities Act for a previous Underwritten Shelf Takedown; 

(iii)    if the Company is not then eligible to use Form S-3 under the
Securities Act; 
 (iv)    if within ten (10) days of receipt of a Demand Shelf Takedown Notice, the
Company gives notice to such Initiating Holder or Holders of the Company’s intention to make a public offering within sixty (60) days, other than pursuant to a Special Registration Statement; provided that the Company makes
reasonable good faith efforts to cause the registration statement relating to the offering to become effective or to file a prospectus supplement pursuant to Rule 424(b) under the Securities Act relating to such offering; 

(v)    if the Initiating Holders, together with the holders of any other securities of the Company entitled to
inclusion in such Underwritten Shelf Takedown, propose to sell Registrable Securities in the Underwritten Shelf Takedown at an aggregate price to the public (before deduction of underwriting discounts and commissions and any Registration Expenses
payable by such Holders) of less than fifty million dollars ($50,000,000); 
 (vi)    if the Company shall
furnish to the Holders a certificate signed by the Chairman of the Board of Directors of the Company stating that in the good faith judgment of the Board of Directors of the Company, it would be seriously detrimental to the Company and its
stockholders for such Underwritten Shelf Takedown to be effected at such time, in which event the Company shall have the right to defer the Underwritten Shelf Takedown for a period of not more than one hundred twenty (120) days after receipt of
the Demand Shelf Takedown Notice; provided that such right to delay an Underwritten Shelf Takedown, together with such rights set forth in Section 2.4(b)(v), shall be exercised by the Company not more than once in any twelve
(12) month period; provided, further, that the Company shall not register any securities for the account of itself or any other stockholder, or consummate any offering of securities pursuant to any registration
statement, during such one hundred twenty (120) day period (in each case other than pursuant to a Special Registration Statement); or 

(vii)    during a Suspension Period. 

2.5    Expenses of Registration. Except as specifically provided herein, (i) all Registration Expenses
(inclusive of one counsel to the Holders not to exceed $30,000 and exclusive of underwriting discounts and commissions, stock transfer taxes, and fees of accountants for the Holders and additional counsel to the Holders) incurred in connection with
any registration, qualification or compliance pursuant to Sections 2.2 or 2.3 herein shall be borne by the Company, and (ii) all Registration Expenses, including Selling Expenses and stock transfer taxes, as well as other Holder expenses,
including fees of accountants and all counsel to the Holders, incurred in connection with any registration, offering, qualification or compliance (including in connection with an Underwritten Shelf Takedown) pursuant to Section 2.4 shall be
borne by the applicable Holders. All Selling Expenses incurred in connection with any registrations hereunder shall be borne by the Holders of the securities so registered and sold pro rata on the basis of the number of shares so registered
and sold. The Company shall not, however, be required to pay for expenses of any registration proceeding begun pursuant to Section 2.2, the request of which has been subsequently withdrawn by the applicable Initiating Holders unless
(a) the withdrawal is based upon material adverse Company-specific information of which such Initiating Holders were not aware at the time of such request, or (b) the Holders of a majority of Registrable Securities (or, in the case of a
registration requested by the Carlyle Initiating Holders, the Carlyle Initiating Holders) agree to deem such registration to have been effected as of the date of such withdrawal for purposes of determining whether the Company shall be 

  
 11 

 
obligated pursuant to Section 2.2(c)(i) to undertake any subsequent registration, in which event such right shall be forfeited by all Holders (or, in the case of a registration requested by
the Carlyle Initiating Holders, the Carlyle Initiating Holders). If the Holders are required to pay the Registration Expenses, such expenses shall be borne by the holders of securities (including Registrable Securities) requesting such registration
or offering in proportion to the number of shares for which registration or sale was requested. 
 2.6    Obligations
of the Company. Whenever required to effect the registration of any Registrable Securities, including to effect an Underwritten Shelf Takedown, the Company shall, at its expense and as expeditiously as reasonably possible: 

(a)    prepare and file with the SEC a registration statement with respect to such Registrable Securities and use
all reasonable efforts to cause such registration statement to become effective, and, upon the request of the Holders of a majority of the Registrable Securities registered thereunder, keep such registration statement effective for up to sixty
(60) days or, if earlier, until the Holder or Holders have completed the distribution related thereto; provided, however, that at any time, upon written notice to the participating Holders and for a period not to exceed sixty
(60) days thereafter (the “Suspension Period”), the Company may delay the effectiveness of any registration statement or suspend the use or effectiveness of any registration statement (and the applicable Initiating Holders
hereby agree not to offer or sell any Registrable Securities pursuant to such registration statement during the Suspension Period), including for Underwritten Shelf Takedowns, if the Company reasonably believes that there is or may be in existence
material nonpublic information or events involving the Company, the failure of which to be disclosed in the prospectus included in the registration statement could result in a Violation (as defined below); and, provided, further, that
in the case of any registration of Registrable Securities on Form S-3 which are intended to be offered on a continuous or delayed basis, such sixty (60) day period shall be extended to a period of one
(1) year. In the event that the Company shall exercise its right to delay or suspend the filing or effectiveness of a registration hereunder, the applicable time period during which the registration statement is to remain effective shall be
extended by a period of time equal to the duration of the Suspension Period. The Company may extend the Suspension Period for an additional consecutive sixty (60) days with the consent of the holders of a majority of the Registrable
Securities registered under the applicable registration statement, which consent shall not be unreasonably withheld. No more than two (2) such Suspension Periods shall occur in any twelve (12) month period. If so directed by the
Company, all Holders registering shares under such registration statement shall (i) not offer to sell any Registrable Securities pursuant to the registration statement during the period in which the delay or suspension is in effect after
receiving notice of such delay or suspension; and (ii) use reasonable efforts to deliver to the Company (at the Company’s expense) all copies, other than permanent file copies then in such Holders’ possession, of the prospectus
relating to such Registrable Securities current at the time of receipt of such notice. Notwithstanding the foregoing, the Company shall not be required to file, cause to become effective or maintain the effectiveness of any registration statement
other than a registration statement on Form S-3 that contemplates a distribution of securities on a delayed or continuous basis pursuant to Rule 415 under the Securities Act. Before filing a registration
statement, the Company will furnish the Holders of Registrable Securities covered by such registration statement, the underwriters, if any, and any attorney, accountant or other agent retained by any such Holders of Registrable Securities or
underwriters copies of all such documents proposed to be filed, which documents will be subject to reasonable review and comment of such Holders, their counsel and underwriters, if any, and will not file any registration statement to which the
Holders of at least a majority of the Registrable Securities covered by such registration statement or the underwriter, if any, shall, for reasonable reasons, object. 

(b)    Prepare and file with the SEC such amendments and supplements to such registration statement and the
prospectus used in connection with such registration statement as may be necessary to keep such registration statement effective or comply with the provisions of the Securities Act with respect to the disposition of all securities covered by such
registration statement for the period set forth in subsection (a) above. 

  
 12 

 (c)    Furnish to the Holders, without charge, such number of
copies of a prospectus including a preliminary prospectus, and any amendment of or supplement to the prospectus or any issuer free writing prospectus, in conformity with the requirements of the Securities Act, and such other documents as they may
reasonably request in order to facilitate the disposition of Registrable Securities owned by them. 
 (d)    Use
its reasonable efforts to register and qualify the securities covered by such registration statement under such other securities or Blue Sky laws of such jurisdictions as shall be reasonably requested by the Holders to keep such registration and
qualification in effect for so long as the registration statement remains in effect, and to take any other action which may be reasonably necessary or advisable to enable such Holder to consummate the disposition in such jurisdictions of the
securities owned by such Holder; provided that the Company shall not be required in connection therewith or as a condition thereto to qualify to do business or to file a general consent to service of process in any such states or
jurisdictions. 
 (e)    In the event of any underwritten public offering, enter into and perform its obligations
under an underwriting agreement, in usual and customary form, with the managing underwriter(s) of such offering. Except as otherwise provided herein, each Holder participating in such underwriting shall also enter into and perform its obligations
under such an agreement. 
 (f)    Notify each Holder of Registrable Securities covered by such registration
statement at any time when a prospectus relating thereto is required to be delivered under the Securities Act of the happening of any event as a result of which the prospectus included in such registration statement, as then in effect, includes an
untrue statement of a material fact or omits to state a material fact required to be stated therein or necessary to make the statements therein not misleading or incomplete in the light of the circumstances then existing. The Company will use
reasonable efforts to amend or supplement such prospectus in order to cause such prospectus not to include any untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary to make the statements
therein not misleading or incomplete in light of the circumstances then existing. 
 (g)    (i) Use its
reasonable efforts to furnish, if such securities are being sold through underwriters, (A) an opinion, dated the date that such Registrable Securities are delivered to the underwriters for sale, of the counsel representing the Company for the
purposes of such registration, in form and substance as is customarily given to underwriters in an underwritten public offering, addressed to the underwriters, if any, and (B) letters, dated the date of the underwriting agreement relating to
the sale of such Registrable Securities and the date that such Registrable Securities are delivered to the underwriters for sale, from the independent certified public accountants of the Company, in form and substance as is customarily given by
independent certified public accountants to underwriters in an underwritten public offering addressed to the underwriters, if any, and to the Holders requesting registration of Registrable Securities, and (ii) in connection with any
underwritten public offering of Registrable Securities, only upon the reasonable request of the managing underwriters for such offering, agree to, and cause its directors and executive officers to enter into, a
lock-up provision in an underwriting agreement or lock-up agreements, as applicable, in each case in customary form and substance, with a
lock-up period no greater than ninety (90) days following the execution of the underwriting agreement relating to such underwritten public offering, and with customary exceptions, including (A) the
establishment of trading plans pursuant to Rule 10b5-1 under the Exchange Act for the transfer of shares of Common Stock (provided that such plan does not provide for the transfer of Common Stock during the lock-up period) and (B) transfers of Common Stock under any such trading plan in existence on the date of execution of an underwriting agreement for such underwritten public offering. 

  
 13 

 (h)    Comply (and continue to comply) with all applicable rules
and regulations of the SEC (including, without limitation, maintaining disclosure controls and procedures (as defined in Exchange Act Rule 13a-15(e)) and internal control over financial reporting (as defined
in Exchange Act Rule 13a-15(f)) in accordance with the Exchange Act), and make generally available to its security holders, as soon as reasonably practicable after the effective date of the registration
statement (and in any event within forty-five (45) days, or ninety (90) days if it is a fiscal year, after the end of such twelve-month (12) period described hereafter), an earnings statement (which need not be audited) covering the
period of at least twelve (12) consecutive months beginning with the first day of the Company’s first calendar quarter after the effective date of the registration statement, which earnings statement shall satisfy the provisions of
Section 11(a) of the Securities Act and Rule 158 thereunder. 
 (i)    (i) (A) cause all such
Registrable Securities covered by such registration statement to be listed on the principal securities exchange on which similar securities issued by the Company are then listed (if any), if the listing of such Registrable Securities is then
permitted under the rules of such exchange, or (B) if no similar securities are then so listed, to either cause all such Registrable Securities to be listed on a national securities exchange and, without limiting the generality of the
foregoing, take all actions that may be required by the Company as the issuer of such Registrable Securities in order to facilitate the managing underwriter’s arranging for the registration of at least two market makers as such with respect to
such shares with FINRA, and (ii) comply (and continue to comply) with the requirements of any self-regulatory organization applicable to the Company, including without limitation all corporate governance requirements. 

(j)    Provide and cause to be maintained a transfer agent and registrar for all such Registrable Securities
covered by such registration statement not later than the effective date of such registration statement. 

(k)    Provide a CUSIP number for all Registrable Securities not later than the effective date of the registration
statement. 
 (l)    Use its commercially reasonable efforts to make available its employees and personnel for
participation in “road shows” and other marketing efforts and otherwise provide reasonable assistance to the underwriters (taking into account the needs of the Company’s businesses and the requirements of the marketing process) in the
marketing of Registrable Securities in any underwritten offering. 
 (m)    Use its commercially reasonable
efforts to prevent the entry of any order suspending the effectiveness of the registration statement and, in the event of the issuance of any such stop order, or of any order suspending or preventing the use of any related prospectus or suspending
the qualification of any security included in such registration statement for sale in any jurisdiction, the Company shall use its commercially reasonable efforts promptly to obtain the withdrawal of such order at the earliest possible time. 

To the extent the Company is a well-known seasoned issuer (as defined in Rule 405 under the Securities Act) (a “WKSI”) at the
time any demand registration request is submitted to the Company pursuant to Section 2.4 above, and such demand registration request requests that the Company file an automatic shelf registration statement (as defined in
Rule 405 under the Securities Act) (an “automatic shelf registration statement”) on Form S-3, the Company shall file an automatic shelf registration statement which covers those Registrable
Securities which are requested to be registered. The Company shall use its 

  
 14 

 
commercially reasonable efforts to remain a WKSI (and not become an ineligible issuer (as defined in Rule 405 under the Securities Act)) during the period during which such automatic shelf
registration statement is required to remain effective. If the Company does not pay the filing fee covering the Registrable Securities at the time the automatic shelf registration statement is filed, the Company agrees to pay such fee at such time
or times as the Registrable Securities are to be sold. If the automatic shelf registration statement has been outstanding for at least three (3) years, at the end of the third year the Company shall refile a new automatic shelf registration
statement covering the Registrable Securities. If, at any time when the Company is required to re-evaluate its WKSI status, the Company determines that it is not a WKSI, the Company shall use its commercially
reasonable efforts to refile the shelf registration statement on Form S-3 and, if such form is not available, Form S-1 and keep such registration statement effective
during the period during which such registration statement is required to be kept effective. 
 If the Company files any shelf registration
statement for the benefit of the holders of any of its securities other than the Holders, the Company agrees that it shall include in such registration statement such disclosures as may be required by Rule 430B under the Securities Act (referring to
the unnamed selling security holders in a generic manner by identifying the initial offering of the securities to the Holders) in order to ensure that the Holders may be added to such shelf registration statement at a later time through the filing
of a prospectus supplement rather than a post-effective amendment. 
 2.7    Delay of Registration; Furnishing
Information. 
 (a)    No Holder shall have any right to obtain or seek an injunction restraining or otherwise
delaying any such registration as the result of any controversy that might arise with respect to the interpretation or implementation of this Section 2. 

(b)    It shall be a condition precedent to the obligations of the Company to take any action pursuant to
Section 2.2, 2.3 or 2.4 that the selling Holders shall furnish to the Company such information regarding themselves, the Registrable Securities held by them and the intended method of disposition of such securities as shall be required to
effect the registration of their Registrable Securities. 
 (c)    The Company shall have no obligation with
respect to any registration requested pursuant to Section 2.2 or Section 2.4 if the number of shares or the anticipated aggregate offering price of the Registrable Securities to be included in the registration does not equal or exceed the
number of shares or the anticipated aggregate offering price required to originally trigger the Company’s obligation to initiate such registration as specified in Section 2.2 or Section 2.4, whichever is applicable. 

2.8    Indemnification. In the event any Registrable Securities are included in a registration statement under
Section 2.2, 2.3 or 2.4: 
 (a)    To the extent permitted by law, the Company will indemnify and hold
harmless each Holder, the partners, members, officers and directors of each Holder, any underwriter (as defined in the Securities Act) for such Holder and each person, if any, who controls such Holder or underwriter within the meaning of the
Securities Act or the Exchange Act, against any losses, claims, damages, liabilities (joint or several), costs or expenses (or actions, proceedings or settlements in respect thereof) to which they may become subject under the Securities Act, the
Exchange Act or other federal or state law, insofar as such losses, claims, damages, liabilities, costs or expenses (or actions, proceedings or settlements in respect thereof) arise out of or are based upon any of the following statements, omissions
or violations (collectively a “Violation”) by the Company: (i) any untrue statement or alleged untrue statement of a material fact contained in such registration statement or incorporated by reference therein, including any
preliminary prospectus, final prospectus or issuer free writing prospectus contained therein or any amendments or supplements thereto, (ii) the omission or alleged omission to state therein a material fact required to be

  
 15 

 
stated therein, or necessary to make the statements therein not misleading, or (iii) any violation or alleged violation by the Company of the Securities Act, the Exchange Act, any other
federal, state securities law or any rule or regulation promulgated under the Securities Act, the Exchange Act or any other federal, state securities law in connection with the offering covered by such registration statement; and the Company will
reimburse each such Holder, partner, member, officer, director, underwriter or controlling person for any legal or other expenses reasonably incurred by them, as such expenses are incurred, in connection with investigating or defending any such
loss, claim, damage, liability or action, as incurred; provided, however, that the indemnity agreement contained in this Section 2.8(a) shall not apply to amounts paid in settlement of any such loss, claim, damage,
liability or action if such settlement is effected without the consent of the Company, which consent shall not be unreasonably withheld, nor shall the Company be liable in any such case for any such loss, claim, damage, liability or action to the
extent that it arises out of or is based upon a Violation which occurs in reliance upon and in conformity with written information furnished expressly for use in connection with such registration by such Holder, partner, member, officer, director,
underwriter or controlling person of such Holder. 
 (b)    To the extent permitted by law, each Holder will, if
Registrable Securities held by such Holder are included in the securities as to which such registration, qualifications or compliance is being effected, indemnify and hold harmless the Company, each of its directors, its officers and each person, if
any, who controls the Company within the meaning of the Securities Act, any underwriter and any other Holder selling securities under such registration statement or any of such other Holder’s partners, members, directors or officers or any
person who controls such Holder, against any losses, claims, damages, liabilities (joint or several), costs or expenses (or actions, proceedings or settlements in respect thereof) to which the Company or any such director, officer, controlling
person, underwriter or other such Holder, or partner, member, director, officer or controlling person of such other Holder may become subject under the Securities Act, the Exchange Act or other federal or state law, insofar as such losses, claims,
damages, liabilities, costs or expenses (or actions, proceedings or settlements in respect thereof) arise out of or are based upon any of the following statements: (i) any untrue statement or alleged untrue statement of a material fact
contained in such registration statement or incorporated by reference therein, including any preliminary prospectus, final prospectus or issuer free writing prospectus contained therein or any amendments or supplements thereto, (ii) the
omission or alleged omission to state therein a material fact required to be stated therein, or necessary to make the statements therein not misleading, or (iii) any violation or alleged violation by the Company of the Securities Act
(collectively, a “Holder Violation”), in each case to the extent (and only to the extent) that such Holder Violation occurs in reliance upon and in conformity with written information furnished by such Holder under an instrument
duly executed by such Holder and stated to be specifically for use in connection with such registration; and each such Holder will reimburse any legal or other expenses reasonably incurred by the Company or any such director, officer, controlling
person, underwriter or other Holder, or partner, officer, director or controlling person of such other Holder in connection with investigating or defending any such loss, claim, damage, liability or action if it is judicially determined that there
was such a Holder Violation; provided, however, that the indemnity agreement contained in this Section 2.8(b) shall not apply to amounts paid in settlement of any such loss, claim, damage, liability or action if such
settlement is effected without the consent of the Holder, which consent shall not be unreasonably withheld; provided, further, that in no event shall any indemnity under this Section 2.8(b) exceed the net proceeds from the
offering received by such Holder and such Holder will not be liable for any amount paid in settlement of any such claim, loss, damage, liability or action if such settlement is effected without the written consent of such Holder, which consent shall
not be unreasonably withheld, conditioned or delayed. 
 (c)    Promptly after receipt by an indemnified party
under this Section 2.8 of notice of the commencement of any action (including any governmental action), such indemnified party will, if a claim in respect thereof is to be made against any indemnifying party under this Section 2.8, deliver
to the indemnifying party a written notice of the commencement thereof and the indemnifying party shall have 

  
 16 

 
the right to participate in, and, to the extent the indemnifying party so desires, jointly with any other indemnifying party similarly noticed, to assume the defense thereof with counsel mutually
satisfactory to the parties; provided, however, that an indemnified party shall have the right to retain its own counsel, with the fees and expenses thereof to be paid by the indemnifying party, if representation of such
indemnified party by the counsel retained by the indemnifying party would be inappropriate due to actual or potential differing interests between such indemnified party and any other party represented by such counsel in such proceeding or if the
indemnified party shall have reasonably concluded that there may be reasonable defenses available to it which are different from or additional to those available to the indemnifying party. The failure to deliver written notice to the indemnifying
party within a reasonable time of the commencement of any such action shall relieve such indemnifying party of any liability to the indemnified party under this Section 2.8 to the extent, and only to the extent, materially prejudicial to its
ability to defend such action, but the omission so to deliver written notice to the indemnifying party will not relieve it of any liability that it may have to any indemnified party otherwise than under this Section 2.8. 

(d)    If the indemnification provided for in this Section 2.8 is held by a court of competent jurisdiction to
be unavailable to an indemnified party with respect to any losses, claims, damages, liabilities, costs or expenses referred to herein, the indemnifying party, in lieu of indemnifying such indemnified party thereunder, shall to the extent permitted
by applicable law contribute to the amount paid or payable by such indemnified party as a result of such loss, claim, damage or liability in such proportion as is appropriate to reflect (i) in the case of a Company-initiated registration under
Section 2.2, the relative benefits received by the Company on the one hand and the Holders whose Registrable Securities are included in the registration on the other hand, and (ii) in all cases, the relative fault of the indemnifying party
on the one hand and of the indemnified party on the other in connection with the Violation(s) or Holder Violation(s) that resulted in such loss, claim, damage, liability, cost or expense as well as any other relevant equitable considerations. The
relative fault of the indemnifying party and of the indemnified party shall be determined by a court of law by reference to, among other things, whether the untrue or alleged untrue statement of a material fact or the omission to state a material
fact relates to information supplied by the indemnifying party or by the indemnified party and the parties’ relative intent, knowledge, access to information and opportunity to correct or prevent such statement or omission; provided,
that (i) in no event shall any contribution by a Holder under this Section 2.8 (including any amounts paid by such Holder pursuant to Section 2.8(b)) exceed the net proceeds from the offering received by such Holder (ii) the
liability of each Holder to contribute as described herein shall be several and not joint, and (iii) no person or entity guilty of fraudulent misrepresentation (within the meaning of Section 11(f) of the Securities Act) will be entitled to
contribution from any person or entity who was not guilty of such fraudulent misrepresentation. 
 (e)    Unless
otherwise superseded by an underwriting agreement entered into in connection with the underwritten public offering, the obligations of the Company and Holders under this Section 2.8 shall survive completion of any offering of Registrable
Securities in a registration statement and, with respect to liability arising from an offering to which this Section 2.8 would apply that is covered by a registration filed before termination of this Agreement, such termination. No indemnifying
party, in the defense of any such claim or litigation, shall, except with the consent of each indemnified party, consent to entry of any judgment or enter into any settlement which does not include as an unconditional term thereof the giving by the
claimant or plaintiff to such indemnified party of a release from all liability in respect to such claim or litigation. 

2.9    Assignment of Registration Rights. The rights to cause the Company to register Registrable
Securities pursuant to this Section 2 may be assigned by a Holder to a transferee or assignee of Registrable Securities (for so long as such shares remain Registrable Securities) that (a) is a partner, retired partner or Affiliate of any
Holder; (b) is a Holder’s family member or trust for the benefit of an individual Holder, or (c) holds at least one hundred thousand (100,000) shares of Registrable Securities (as adjusted

  
 17 

 
for stock splits and combinations) immediately after such transfer; provided, however, (i) the transferor shall, within ten (10) days after such transfer,
furnish to the Company written notice of the name and address of such transferee or assignee and the securities with respect to which such registration rights are being assigned and (ii) such transferee shall agree to be subject to all
restrictions set forth in this Agreement. 
 2.10    Limitation on Subsequent Registration Rights. After
the date of this Agreement, the Company shall not enter into any agreement with any holder or prospective holder of any securities of the Company that would grant such holder rights to demand the registration of shares of the Company’s capital
stock, or to include such shares in a registration statement, unless, under the terms of such agreement, such rights are subordinate to the rights of the Holders or are approved by a majority in interest of the Registrable Securities then
outstanding. 
 2.11    “Market Stand-Off” Agreement. Each
Holder hereby agrees that such Holder shall not sell, transfer, make any short sale of, grant any option for the purchase of, or enter into any hedging or similar transaction with the same economic effect as a sale, any Common Stock (or other
securities) of the Company held by such Holder immediately prior to the effectiveness of the registration statement for such offering (other than those included in the registration or acquired in or following such registration) during the 180-day period following the effective date of the Initial Offering (or such longer period, not to exceed 18 days after the expiration of the 180-day period, as the
underwriter and the Company may request in order to comply with applicable regulations), and that such Holder shall execute the standard lock-up agreement used in the Initial Offering; provided that all
officers and directors of the Company and holders of at least one percent (1%) of the Company’s voting securities are bound by and have entered into similar agreements. The obligations described in this Section 2.11 shall only apply to the
Initial Offering and shall not apply to (i) the sale of any shares to an underwriter pursuant to an underwriting agreement, (ii) a registration relating solely to employee benefit plans on Form S-1
or Form S-8 or similar forms that may be promulgated in the future, or (iii) a registration relating solely to a transaction on Form S-4 or similar forms that may
be promulgated in the future. Any discretionary waiver or termination of the restrictions of any or all of such agreements by the Company or the underwriters shall apply to all Holders subject to such agreements pro rata based on the number of
shares subject to such agreements, unless waived by a majority of the then-outstanding Registrable Securities. The Company covenants that any subsequent Holder of Registrable Securities will be bound by a market
stand-off agreement as defined in this Section 2.11. 

2.12    Agreement to Furnish Information. Each Holder agrees to execute and deliver such other agreements as may be
reasonably requested by the Company or the underwriter that are consistent with the Holder’s obligations under Section 2.11 or that are necessary to give further effect thereto. In addition, if requested by the Company or the
representative of the underwriters of Common Stock (or other securities) of the Company, each Holder shall provide, within ten (10) days of such request (or two (2) Business Days, in the case of an Underwritten Shelf Takedown), such
information as may be reasonably required by the Company or such representative in connection with the completion of any public offering of the Company’s securities pursuant to a registration statement filed under the Securities Act. The
obligations described in Section 2.11 and this Section 2.12 shall not apply to a Special Registration Statement. The Company may impose stop-transfer instructions with respect to the shares of Common Stock (or other securities) subject to
the foregoing restriction until the end of said day period. Each Holder agrees that any transferee of any shares of Registrable Securities shall be bound by Sections 2.11 and 2.12. The underwriters of the Company’s stock are intended third
party beneficiaries of Sections 2.11 and 2.12 and shall have the right, power and authority to enforce the provisions hereof as though they were a party hereto. 

  
 18 

 2.13    Rule 144 Reporting. With a view to making
available to the Holders the benefits of certain rules and regulations of the SEC which may permit the sale of the Registrable Securities to the public without registration, the Company agrees to use its best efforts to: 

(a)    Make and keep public information available, as those terms are understood and defined in SEC Rule 144
or any similar or analogous rule promulgated under the Securities Act, at all times after the effective date of the first registration filed by the Company for an offering of its securities to the general public; 

(b)    File with the SEC, in a timely manner, all reports and other documents required of the Company under the
Exchange Act; and 
 (c)    So long as a Holder owns any Registrable Securities, furnish to such Holder forthwith
upon request: a written statement by the Company as to its compliance with the reporting requirements of said Rule 144 of the Securities Act, and of the Exchange Act (at any time after it has become subject to such reporting requirements); a copy of
the most recent annual or quarterly report of the Company filed with the Commission; and such other reports and documents as a Holder may reasonably request in connection with availing itself of any rule or regulation of the SEC allowing it to sell
any such securities without registration. 
 2.14    Termination. Sections 2.2 through 2.13 of this Agreement
shall terminate and be of no further force or effect upon the earliest of (i) the consummation of an Acquisition or Asset Transfer in which the holders of the Company’s capital stock receive cash or securities from a company subject to the
reporting requirements of Section 12 of the Exchange Act in exchange for their equity interest in the Company; (ii) the date that is seven (7) years following the closing of the Qualified Public Offering; or (iii) with respect to
a particular Holder, such time as all Registrable Securities of such Holder may be sold pursuant to Rule 144 during any ninety (90) day period. Upon such termination, such shares shall cease to be “Registrable Securities” for all
purposes. 
 SECTION 3. COVENANTS OF THE COMPANY. 

3.1    Basic Financial Information. 

(a)    So long as an Investor (with its Affiliates) shall own not less than 1,000,000 shares of Registrable
Securities (as adjusted for stock splits and combinations) (a “Major Investor”), the Company will furnish each Major Investor, as soon as practicable after the end of each fiscal year of the Company, and in any event within one
hundred eighty (180) days thereafter, a balance sheet of the Company, as at the end of such fiscal year, and a statement of income and a statement of cash flows of the Company, for such year, all prepared in accordance with United States
generally accepted accounting principles consistently applied (except as noted therein) and setting forth in each case in comparative form the figures for the previous fiscal year, all in reasonable detail. Such financial statements shall be
accompanied by a report and opinion thereon by independent public accountants selected by the Company’s Board of Directors including the directors elected by the holders of Series B Stock, Series C Stock, Series D Stock, Series E Stock, Series
F Stock, Series G Stock and Series I Stock. If the Company has any subsidiary whose accounts are consolidated with those of the Company for any period, then in respect of such period the financial statements delivered pursuant to this
Section 3.1(a) shall be the consolidated and consolidating financial statements of the Company and all such consolidated subsidiaries. 

(b)    The Company will furnish each Major Investor, as soon as practicable after the end of the quarterly
accounting periods in each fiscal year of the Company, and in any event within forty-five (45) days thereafter, a balance sheet of the Company as of the end of each such quarterly period, and a statement of income and a statement of cash
flows of the Company for such period and for the current fiscal year to date (with monthly detail and a statement of the Company’s headcount for each quarterly period if requested by an Investor), prepared in accordance with United States
generally accepted accounting 

  
 19 

 
principles consistently applied (except as noted therein), with the exception that no notes need be attached to such statements and year-end audit
adjustments may not have been made. If the Company has any subsidiary whose accounts are consolidated with those of the Company for any period, then in respect of such period the financial statements delivered pursuant to this Section 3.1(b)
shall be the consolidated and consolidating financial statements of the Company and all such consolidated subsidiaries. 

(c)    The Company will furnish each Major Investor, as soon as practicable after the end of each of the
Company’s quarterly accounting periods in each fiscal year of the Company, and in any event within forty-five (45) days thereafter, a detailed capitalization table of the Company, including a list of the Company’s outstanding
convertible securities, which list shall include the face amount, issue date, maturity date, interest rate, conversion discount, change of control premium and valuation cap to the extent applicable. 

(d)    The Company will furnish each Major Investor, as soon as practicable after the end of each month in each
fiscal year of the Company, and in any event within fifteen (15) days thereafter, a balance sheet of the Company as of the end of each such monthly period, and a statement of income and a statement of cash flows of the Company for such
monthly period and for the current fiscal year to date, prepared in accordance with United States generally accepted accounting principles consistently applied (except as noted therein), with the exception that no notes need be attached to such
statements and year-end audit adjustments may not have been made. If the Company has any subsidiary whose accounts are consolidated with those of the Company for any period, then in respect of such period the
financial statements delivered pursuant to this Section 3.1(d) shall be the consolidated and consolidating financial statements of the Company and all such consolidated subsidiaries. 

(e)    The Company will furnish each Major Investor, as soon as practicable before the end of each fiscal year of
the Company, and in any event within thirty (30) days beforehand, a budget and business plan for the next fiscal year that has been approved by the Company’s Board of Directors. 

(f)    The Company will furnish each Major Investor such other information relating to the financial condition,
business prospects, or corporate affairs of the Company as any Major Investor may from time to time reasonably request. 

3.2    Inspection Rights. Each Major Investor shall have the right to visit and inspect any of the properties of
the Company or any of its subsidiaries, and to discuss the affairs, finances and accounts of the Company or any of its subsidiaries with its officers, and to review such information as is reasonably requested all at such reasonable times and as
often as may be reasonably requested; provided, however, that the Company shall not be obligated under this Section 3.2 with respect to a competitor of the Company or with respect to information which the Board of Directors
determines in good faith is confidential or attorney-client privileged and should not, therefore, be disclosed. 

3.3    Confidentiality of Records. Each Investor agrees to use the same degree of care as such Investor uses to
protect its own confidential information to keep confidential any information furnished to such Investor pursuant to Section 3.1 or 3.2 hereof that the Company identifies as being confidential or proprietary (so long as such information is not
in the public domain), except that such Investor may disclose such proprietary or confidential information (i) to any director, officer, investment committee member, employee, investment adviser, agent or advisor (including, without limitation,
attorneys, accountants, consultants and financial advisors and other professionals) of such Investor (“Representative”) or general partner, actual or potential limited partner, member or other Affiliate of such Investor or any
Representative of any such Affiliate, as long as such Representative, general partner, limited partner, member or other 

  
 20 

 
Affiliate is advised of and agrees or has agreed to be bound by the confidentiality provisions of this Section 3.3 or comparable restrictions; (ii) at such time as it enters the public
domain through no fault of such Investor; (iii) that is communicated to it free of any obligation of confidentiality; (iv) that is developed by Investor or its agents independently of and without reference to any confidential information
communicated by the Company or its Representative; (v) as required by applicable law or regulation, regulatory body, stock exchange, court or administrative order, or any listing or trading agreement applicable to such Investor; provided
that, if it is reasonably practicable and legally permitted to do so, Investor gives the Company prompt written notice of such requirement prior to such disclosure and Investor gives assistance in obtaining an order protecting the information from
public disclosure; or (vi) as otherwise agreed by the Company in writing. 
 3.4    Stock Vesting. Unless
otherwise approved by the Board of Directors (including the directors elected by the holders of Series B Stock, Series C Stock, Series D Stock, Series E Stock, Series F Stock, Series G Stock and Series I Stock), all stock options and other stock
equivalents issued after the date of this Agreement to employees, directors, consultants and other service providers shall be subject to (i) vesting as follows: (a) twenty-five percent (25%) of such stock shall vest at the end of the first
year following such person’s services commencement date with the Company, and (b) seventy-five percent (75%) of such stock shall vest over the remaining three (3) years; and (ii) a one hundred eighty (180) day lockup period
in connection with the Company’s initial registered public offering of Equity Securities. The Company shall retain a right of first refusal on transfers until the Company’s Initial Offering and the right to repurchase unvested shares at
cost. 
 3.5    Qualified Small Business Stock. The Company will use commercially reasonable efforts to comply
with the reporting and record keeping requirements of Section 1202(d)(1)(C) of the Internal Revenue Code of 1986, as amended (the “Code”), and the regulations thereunder, and during the one year period commencing on the initial
Closing Date (as defined in the Purchase Agreement), the Company will not purchase any of its capital stock or permit any of its subsidiaries to purchase any of the Company’s capital stock in excess of the limitations set forth in
Section 1202(c) of the Code, so long as the Company’s Board of Directors determines that it is in the best interests of and not unduly burdensome to the Company to comply with the provisions of Section 1202 of the Code. At the
reasonable request of an Investor, the Company shall make a determination of whether the Shares (or their underlying Common Stock) constitute “qualified small business stock” within the meaning of Sections 1045 and 1202 of the Code and
shall advise such Investors in writing of such determination within ten (10) days of the receipt of such request. Pursuant to such request by the Investors, the Company will provide information to support the “qualified small business
stock” determination which may include financial statements, tax returns, and other documents that may be desired. 

3.6    Proprietary Information and Inventions Agreements. The Company shall require all employees and consultants
with access to confidential information to execute and deliver a Proprietary Information and Inventions Agreement or Consulting Agreement, as applicable, in substantially the forms approved by the Company’s Board of Directors. 

3.7    Termination of Covenants. All covenants of the Company contained in Section 3 of this Agreement (other
than the provisions of Sections 3.4 and 3.7) shall expire and terminate as to each Investor upon the earlier of (i) the effective date of the registration statement pertaining to an Initial Offering that results in all of the then-outstanding
shares of Preferred Stock being converted into Common Stock or (ii) upon an “Asset Transfer” or “Acquisition,” each as defined in the Company’s Amended and Restated Certificate of Incorporation as in effect as of the
date hereof, in which the holders of the Company’s capital stock receive cash or publicly traded securities in exchange for their equity interest in the Company. 

  
 21 

 SECTION 4. RIGHTS OF FIRST REFUSAL. 

4.1    Subsequent Offerings. Subject to applicable securities laws, (i) each Investor, so long as it
holds Shares (or shares of Common Stock issued upon conversion of such Shares), shall have a right of first refusal to purchase its pro rata share of all Equity Securities, as defined below, that the Company may, from time to time, propose to
sell and issue after the date of this Agreement, other than the Equity Securities excluded by Section 4.7 hereof (the “Offered Securities”) (in each case, that share of Offered Securities to which an Investor is entitled to
subscribe is referred to herein as a “Subscription Share”). An Investor’s pro rata share is equal to the ratio of (a) the number of shares of the Company’s Common Stock (including all shares of Common Stock
issuable or issued upon conversion of the Shares or upon the exercise of outstanding warrants or options) of which such Investor is deemed to be a holder immediately prior to the issuance of such Equity Securities to (b) the total number of
shares of the Company’s outstanding Common Stock (including all shares of Common Stock issued or issuable upon conversion of the Shares or upon the exercise of any outstanding warrants or options) immediately prior to the issuance of the Equity
Securities. The term “Equity Securities” shall mean (i) any Common Stock, Preferred Stock or other security of the Company, (ii) any security convertible into or exercisable or exchangeable for, with or without
consideration, any Common Stock, Preferred Stock or other security (including any option to purchase such a convertible security), (iii) any security carrying any warrant or right to subscribe to or purchase any Common Stock, Preferred Stock or
other security or (iv) any such warrant or right. 
 4.2    Exercise of Rights. If the Company proposes to
issue any Equity Securities, it shall give each Investor written notice of its intention, describing the Equity Securities, the price and the terms and conditions upon which the Company proposes to issue the same. Each Investor shall have twenty
(20) days from the giving of such notice to agree to purchase up to its applicable Subscription Share of the Equity Securities for the price and upon the terms and conditions specified in the notice by giving written notice to the
Company and stating therein the quantity of Equity Securities to be purchased. The Company shall promptly, in writing, inform each Investor that elects to purchase all the shares available to it (a
“Fully-Exercising Investor”) of any other Investor’s failure to do likewise. During the ten (10) day period commencing after such information is given, each Fully-Exercising Investor may elect to purchase a portion of the then unsubscribed Offered Securities. Each Fully-Exercising Investor will have the right to purchase up to its Oversubscription Share of the
unsubscribed Offered Securities. Notwithstanding the foregoing, the Company shall not be required to offer or sell such Equity Securities to any Investor who would cause the Company to be in violation of applicable federal securities laws by virtue
of such offer or sale. For purposes hereof, a Fully-Exercising Investor’s “Oversubscription Share” is equal to the ratio of (a) the number of shares of the Company’s Common Stock (including all shares of Common Stock
issuable or issued upon conversion of the Shares or upon the exercise of outstanding warrants or options) of which such Fully-Exercising Investor is deemed to be a holder immediately prior to the issuance of such Equity Securities to (b) the
total number of shares of the Company’s Common Stock (including all shares of Common Stock issued or issuable upon conversion of the Shares or upon the exercise of any outstanding warrants or options) deemed to be held by all Fully-Exercising
Investors immediately prior to the issuance of the Equity Securities. An Investor shall be entitled to apportion the right to purchase Offered Securities hereby granted to it among itself and its Affiliates in such proportions as it deems
appropriate. The failure by any Holder to exercise its option to purchase Offered Securities with respect to one offering, sale or issuance shall not affect its option to purchase Offered Securities in any subsequent offering, sale or issuance. 

4.3    Issuance of Equity Securities to Other Persons. The Company shall have sixty (60) days thereafter to
sell the Equity Securities in respect of which the Investors’ rights were not exercised, at a price and upon general terms and conditions not materially more favorable to the purchasers thereof than specified in the Company’s notice to the
Investors pursuant to Section 4.2 hereof. If the Company has not sold such Equity Securities within sixty (60) days of the notice provided pursuant to Section 4.2, the Company shall not thereafter issue or sell any Equity Securities,
without first offering such securities to the Investors in the manner provided above. 

  
 22 

 4.4    Sale Without Notice. In lieu of giving notice to
the Investors prior to the issuance of Equity Securities as provided in Section 4.2, the Company may elect to give notice to the Investors within thirty (30) days after the issuance of Equity Securities. Such notice shall describe the
type, price and terms of the Equity Securities. Each Investor shall have twenty (20) days from the date of receipt of such notice to elect to purchase up to the number of shares that would maintain such Investor’s pro rata share of
the Company’s equity securities after giving effect to such issuance. The closing of such sale shall occur within sixty (60) days of the date of notice to the Investors. The Company shall promptly, in writing, inform each Fully-Exercising
Investor that elects to purchase all the shares available to it of any other Investor’s failure to do likewise. During the ten (10) day period commencing after such information is given, each Fully-Exercising Investor may elect to up to
its Oversubscription Share of the unsubscribed Equity Securities. Notwithstanding the foregoing, the Company shall not be required to offer or sell such Equity Securities to any Investor who would cause the Company to be in violation of applicable
federal securities laws by virtue of such offer or sale. 
 4.5    Termination and Waiver of Rights of First
Refusal. The rights of first refusal established by this Section 4 shall not apply to, and shall terminate upon the earlier of (i) the effective date of a “Qualified Public Offering,” as defined in the
Company’s Amended and Restated Certificate of Incorporation, as may be amended from time to time, or (ii) the consummation of an Acquisition or Asset Transfer. 

4.6    Assignment of Rights of First Refusal. The rights of first refusal of each Investor under this
Section 4 may be assigned to the same parties, subject to the same restrictions as any transfer of registration rights pursuant to Section 2.9. 

4.7    Excluded Securities. The rights of first refusal established by this Section 4 shall have no
application to any of the Equity Securities (i) that are excluded as “Additional Shares of Common Stock” pursuant to Article IV(D)(5)(h)(viii) of the Company’s Amended and Restated Certificate of Incorporation, as may be amended
from time to time, and (ii) that are issued by the Company pursuant to the terms of Section 2.4 of the Purchase Agreement. 
 SECTION 5.
MISCELLANEOUS. 
 5.1    Governing Law. This Agreement shall be governed by and construed under the laws of
the State of Delaware, without reference to conflicts of laws or principles thereof. Any controversy between the parties hereto involving any claim arising out of or relating to the termination of this Agreement, will be submitted to and be settled
by final and binding arbitration in San Francisco County, in accordance with the then current Commercial Arbitration Rules of the American Arbitration Association (the “AAA”), and judgment upon the award rendered by the arbitrators
may be entered in any court having jurisdiction thereof. Such arbitration shall be conducted by three (3) arbitrators chosen by the Company and the Purchasers, or failing such agreement, an arbitrator appointed by the AAA. There shall be
limited discovery prior to the arbitration hearing as follows: (a) exchange of witness lists and copies of documentary evidence and documents relating to or arising out of the issues to be arbitrated, (b) depositions of all party witnesses
and (c) such other depositions as may be allowed by the arbitrators upon a showing of good cause. Depositions shall be conducted in accordance with the California Code of Civil Procedure, the arbitrator shall be required to provide in writing
to the parties the basis for the award or order of such arbitrator, and a court reporter shall record all hearings, with such record constituting the official transcript of such proceedings. 

5.2    Successors and Assigns. Except as otherwise expressly provided herein, the provisions hereof shall inure to
the benefit of, and be binding upon, the parties hereto and their respective permitted successors, assigns, heirs, executors, and administrators and shall inure to the benefit of and be enforceable by each person who shall be a holder of Registrable
Securities from time to time; provided, however, that 

  
 23 

 
prior to the receipt by the Company of adequate written notice of the transfer of any Registrable Securities specifying the full name and address of the transferee, the Company may deem and treat
the person listed as the holder of such shares in its records as the absolute owner and holder of such shares for all purposes, including the payment of dividends or any redemption price. 

5.3    Entire Agreement. This Agreement, the Exhibits and Schedules hereto, the Purchase Agreement and the other
documents delivered pursuant thereto constitute the full and entire understanding and agreement between the parties with regard to the subjects hereof and no party shall be liable or bound to any other in any manner by any oral or written
representations, warranties, covenants and agreements except as specifically set forth herein and therein. Each party expressly represents and warrants that it is not relying on any oral or written representations, warranties, covenants or
agreements outside of this Agreement. 
 5.4    Severability. In the event one or more of the provisions of this
Agreement should, for any reason, be held to be invalid, illegal or unenforceable in any respect, such invalidity, illegality, or unenforceability shall not affect any other provisions of this Agreement, and this Agreement shall be construed as if
such invalid, illegal or unenforceable provision had never been contained herein. 
 5.5    Amendment and Waiver.

 (a)    Except as otherwise expressly provided, this Agreement may be amended or modified, and the
obligations of the Company and the rights of the Holders under this Agreement may be waived (either generally or in a particular instance and either retroactively or prospectively), only upon the written consent of the Company and the holders of a
majority of the then-outstanding Registrable Securities; provided however that this Agreement shall not be amended without the consent of each Holder or Investor adversely affected if such amendment would modify the
rights or obligations of that Holder or Investor as compared to the rights and obligations of the other Holders or Investors (i.e., if an amendment did not alter ratably the rights and obligations of the Holders or the Investors hereunder);
and provided, further, that notwithstanding the foregoing, Sections 2.14, 3.7 and 5.5 of this Agreement shall not be amended or waived without the written consent of each of Oak Investment Partners XII, Limited Partnership, and
GV 2013, L.P., and Redmile Capital Offshore Fund II, Ltd. and its Affiliates; and provided, further, that notwithstanding the foregoing, Sections 2.11 and 3.1 of this Agreement shall not be amended or waived without the written
consent of Fidelity Select Portfolios: Health Care Portfolio, Fidelity Select Portfolios: Medical Equipment and Systems Portfolio, Fidelity Central Investment Portfolios LLC: Fidelity Health Care Central Fund, Fidelity Advisor Series VII: Fidelity
Advisor Health Care Fund, and Variable Insurance Products Fund IV: Health Care Portfolio; and provided, further, that notwithstanding the foregoing, the rights of holders of Series H Preferred Stock pursuant to Section 4 hereof
may be waived (and this proviso may be amended) only upon the written consent of the holders of a majority of the then-outstanding Series H Preferred Stock; and provided, further, that notwithstanding the foregoing, Sections
2.1(b)(ii), 2.2(a), 2.11, 2.14, 3.1, 3.7 and 5.5 of this Agreement shall not be amended or waived without, and the rights of holders of Series I Preferred Stock pursuant to Section 4 hereof may be waived (and this proviso may be amended) only
upon, in each case, the written consent of Carlyle. 
 (b)    For the purposes of determining the number of
Holders or Investors entitled to vote or exercise any rights hereunder, the Company shall be entitled to rely solely on the list of record holders of its stock as maintained by or on behalf of the Company. 

5.6    Delays or Omissions. It is agreed that no delay or omission to exercise any right, power, or remedy accruing
to any party, upon any breach, default or noncompliance by another party under this Agreement shall impair any such right, power, or remedy, nor shall it be construed to be a waiver of any such breach, default or noncompliance, or any acquiescence
therein, or of any similar breach, default or noncompliance thereafter occurring. It is further agreed that any waiver, permit, consent, or approval of any kind or character on any party’s part of any breach, default or 

  
 24 

 
noncompliance under the Agreement or any waiver on such party’s part of any provisions or conditions of this Agreement must be in writing and shall be effective only to the extent
specifically set forth in such writing. All remedies, either under this Agreement, by law, or otherwise afforded to any party, shall be cumulative and not alternative. 

5.7    Notices. All notices required or permitted hereunder shall be in writing and shall be deemed effectively
given: (a) upon personal delivery to the party to be notified, (b) when sent by confirmed electronic mail or facsimile if sent during normal business hours of the recipient; if not, then on the next business day, (c) five
(5) days after having been sent by registered or certified mail, return receipt requested, postage prepaid, or (d) one (1) day after deposit with a nationally recognized overnight courier, specifying next day delivery, with written
verification of receipt. All communications shall be sent to the party to be notified at the address as set forth on the signature pages hereof or Exhibit A hereto or at such other address or electronic mail address as such party may
designate by ten (10) days advance written notice to the other parties hereto. 
 5.8    Attorneys’ Fees.
In the event that any suit or action is instituted under or in relation to this Agreement, including without limitation to enforce any provision in this Agreement, the prevailing party in such dispute shall be entitled to recover from the losing
party all fees, costs and expenses of enforcing any right of such prevailing party under or with respect to this Agreement, including without limitation, such reasonable fees and expenses of attorneys and accountants, which shall include, without
limitation, all fees, costs and expenses of appeals. 
 5.9    Titles and Subtitles. The titles of the sections
and subsections of this Agreement are for convenience of reference only and are not to be considered in construing this Agreement. 

5.10    Additional Investors. Notwithstanding anything to the contrary contained herein, if the Company shall issue
additional shares of its Series I Stock, any purchaser of such shares of Series I Stock shall become a party to this Agreement by executing and delivering an additional counterpart signature page to this Agreement and shall be deemed an
“Investor,” a “Holder” and a party hereunder. 
 5.11    Counterparts. This
Agreement may be executed in any number of counterparts, each of which shall be an original, but all of which together shall constitute one instrument. 

5.12    Aggregation of Stock. All shares of Registrable Securities held or acquired by Affiliated entities or
persons or persons or entities under common management or control shall be aggregated together for the purpose of determining the availability of any rights under this Agreement. 

5.13    Pronouns. All pronouns contained herein, and any variations thereof, shall be deemed to refer to the
masculine, feminine or neutral, singular or plural, as to the identity of the parties hereto may require. 
 [THIS SPACE INTENTIONALLY LEFT
BLANK] 

  
 25 

 IN WITNESS WHEREOF, the parties hereto
have executed this AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT as of the date set forth in the first paragraph hereof. 

 

			
	COMPANY:
	
	1LIFE HEALTHCARE, INC.
		
	By:	 	 /s/ Amir Dan
Rubin                    

		 	AMIR DAN RUBIN
		 	Chair, Chief Executive Officer and
		 	President

			
		
	Address:	 	One Embarcadero Center, 19th Floor
		 	San Francisco, CA 94111

  
 1LIFE
HEALTHCARE, INC. 
 AMENDED AND RESTATED INVESTOR
RIGHTS AGREEMENT – SIGNATURE PAGE 

 IN WITNESS WHEREOF, the parties hereto
have executed this AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT as of the date set forth in the first paragraph hereof. 

 

			
	INVESTORS:
	
	CARLYLE PARTNERS VII HOLDINGS, L.P.
		
	BY: 	 	TC GROUP VII, L.P., ITS GENERAL PARTNER
	BY: 	 	TC GROUP VII, L.L.C., ITS GENERAL PARTNER
	
	 /s/ Jeremy W. Anderson

	By: 	 	Jeremy W. Anderson
	Title:	 	Authorized Person

  
 1LIFE
HEALTHCARE, INC. 
 AMENDED AND RESTATED INVESTOR
RIGHTS AGREEMENT – SIGNATURE PAGE 

 IN WITNESS WHEREOF, the parties hereto
have executed this AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT as of the date set forth in the first paragraph hereof. 

INVESTORS: 
  

					
	OAK INVESTMENT PARTNERS XII, LIMITED PARTNERSHIP
	By:	 	Oak Associates XII, LLC, its General Partner
		
	By:	 	 /s/ Ann H. Lamont

		 	Name:	 	Ann H. Lamont
		 	Title:	 	Managing Member

  
 1LIFE
HEALTHCARE, INC. 
 AMENDED AND RESTATED INVESTOR
RIGHTS AGREEMENT – SIGNATURE PAGE 

 IN WITNESS WHEREOF, the parties hereto
have executed this AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT as of the date set forth in the first paragraph hereof. 

 

			
	INVESTORS:
	
	BENCHMARK CAPITAL PARTNERS V, L.P.
	as nominee for
	Benchmark Capital Partners V, L.P.
	Benchmark Founders’ Fund V, L.P.
	Benchmark Founders’ Fund V-A, L.P
	Benchmark Founders’ Fund V-B, L.P.
	and related individuals
		
	By:	 	Benchmark Capital Management Co. V, L.L.C.
		 	its general partner
		
	By:	 	 /s/ Steven M. Spurlock

		 	    Steven M. Spurlock, Managing Member

			
		
	Address:	 	2965 Woodside Road
		 	Woodside, CA 94062

  
 1LIFE
HEALTHCARE, INC. 
 AMENDED AND RESTATED INVESTOR
RIGHTS AGREEMENT – SIGNATURE PAGE 

 IN WITNESS WHEREOF, the parties hereto
have executed this AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT as of the date set forth in the first paragraph hereof. 

 

			
	INVESTORS:
	
	GV 2013, L.P.
	By: GV 2013 GP, L.L.C., its General Partner
		
	By:	 	 /s/ Daphne M. Chang

	Name:	 	Daphne M. Chang
	Title:	 	Authorized Signatory
	Address:	 	GV 2013, L.P.
		 	1600 Amphitheatre Parkway
		 	Mountain View, CA 94043
		 	With a copy to: notice@gv.com

  
 1LIFE
HEALTHCARE, INC. 
 AMENDED AND RESTATED INVESTOR
RIGHTS AGREEMENT – SIGNATURE PAGE 

 IN WITNESS WHEREOF, the parties hereto
have executed this AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT as of the
date set forth in the first paragraph hereof. 
  

			
	INVESTORS:
	
	MAVERICK HOLDINGS L, LLC
		
	By:	 	Maverick Capital, Ltd.,
		 	its investment manager
		
	By:	 	 /s/ Ginessa Avila

	Name:	 	Ginessa Avila
	Title:	 	Assistant General Counsel
	
	MAVERICK FUND, L.D.C.
		
	By:	 	Maverick Capital, Ltd.,
		 	its investment manager
		
	By:	 	 /s/ Ginessa Avila

	Name:	 	Ginessa Avila
	Title:	 	Assistant General Counsel
	
	MAVERICK FUND USA, LTD.
		
	By:	 	Maverick Capital, Ltd.,
		 	its investment manager
		
	By:	 	 /s/ Ginessa Avila

	Name:	 	Ginessa Avila
	Title:	 	Assistant General Counsel

  
 1LIFE
HEALTHCARE, INC. 
 AMENDED AND RESTATED INVESTOR
RIGHTS AGREEMENT – SIGNATURE PAGE 

 EXHIBIT A 

SCHEDULE OF INVESTORS 

 

					
	
NAME AND ADDRESS
	  	SERIES A SHARES	 
	 BRICK AND MEG
CONWAY
 686 Capp Street

San Francisco, CA 94110
	  	 	100,000	 
		
	 TODD HENRICH

123 Boway Rd

South Salem, NY 10590
	  	 	60,000	 
		
	 MING AND MINAKO
LEE
 7527 42nd Ave NE

Seattle, WA 98115
	  	 	100,000	 
		
	 THOMAS HO LEE, TRUSTEE
OF THE TXL REVOCABLE TRUST
 1
Hawthorne Street, 23D
 San Francisco, CA 94105
	  	 	400,000	 
		
	 JUSTIN MARTINKOVIC

810 Jones St #307

San Francisco, CA 94109
	  	 	20,000	 
		
	 BRIAN MILFORD

941 Walnut Avenue

Walnut Creek, CA 94598
	  	 	10,000	 
		
	 MOSSER VENTURES

2826 Octavia Street

San Francisco, CA 94123

Attn: Scott Mosser
	  	 	20,000	 
		
	 WILLIAM T. REED AND AMY DAVIRRO,
AS TRUSTEES OF THE WILLIAM REED AND AMY DAVIRRO REVOCABLE TRUST
CREATED 
 U/D/T DATED JUNE 3, 2014

148 Elm Avenue

Mill Valley, CA 94941
	  	 	85,000	 
		
	 LAIRD S.T. REED REVOCABLE
TRUST
 3352 S. Street N.W.

Washington, DC 20007
	  	 	100,000	 
		
	 J. SCOTT SINCLAIR

128 Wythe Avenue, PHD

Brooklyn, NY 11249
	  	 	40,000	 

  
 A-1 

SCHEDULE OF INVESTORS 

					
	
NAME AND ADDRESS
	  	SERIES A SHARES	 
	 JAMES WORKMAN

245 Downey Street

San Francisco, CA 94117
	  	 	50,000	 
		
	 EDWARD WU

77 Hudson Street, Apt. 5

New York, NY 10013
	  	 	50,000	 
		
	 LIFEFORCE CAPITAL, LLC

106 Lincoln Boulevard, Suite 104

San Francisco, CA 94129

Attn: John Noonan
	  	 	25,000	 
		
	 LIFEFORCE-CHS MANAGEMENT-ONE MEDICAL/ 
 1LIFE
HEALTHCARE LLC
 106 Lincoln Boulevard, Suite 104

San Francisco, CA 94129

Attn: John Noonan
	  	 	70,000	 
		
	 TOTAL SERIES A PREFERRED:
	  	 	1,130,000	 
		  	  
	  
	 
		
	
NAME AND ADDRESS
	  	SERIES B SHARES	 
	 BENCHMARK CAPITAL PARTNERS V, L.P.

2965 Woodside Road

Woodside, CA 94062

Attn: Steve Spurlock
	  	 	5,749,630	 
		
	 KENNEDY FAMILY TRUST

3930 Washington St.

San Francisco, CA 94118

Attn: David Kennedy
	  	 	348,462	 
		
	 SAINTS VENTURES II, L.P.

2020 Union Street

San Francisco, CA 94123

Attn: Bob Keppler
	  	 	226,500	 
		
	 TOTAL SERIES B PREFERRED:
	  	 	6,324,592	 
		  	  
	  
	 

  
 A-2 

SCHEDULE OF INVESTORS 

					
	
NAME AND ADDRESS
	  	SERIES C SHARES	 
	 DAG VENTURES IV-QP, L.P.

251 Lytton Avenue, Suite 200

Palo Alto, CA 94301

Tel: (650) 543-8180

Fax: (650) 328-2921
	  	 	3,428,055	 
		
	 DAG VENTURES IV, L.P.

251 Lytton Avenue, Suite 200

Palo Alto, CA 94301

Tel: (650) 543-8180

Fax: (650) 328-2921
	  	 	362,285	 
		
	 DAG VENTURES IV-A, LLC

251 Lytton Avenue, Suite 200

Palo Alto, CA 94301

Tel: (650) 543-8180

Fax: (650) 328-2921
	  	 	1,082,954	 
		
	 BENCHMARK CAPITAL PARTNERS V, L.P.

2965 Woodside Road

Woodside, CA 94062

Attn: Steve Spurlock
	  	 	3,736,192	 
		
	 KENNEDY FAMILY TRUST

3930 Washington St.

San Francisco, CA 94118

Attn: David Kennedy
	  	 	54,148	 
		
	 TOTAL SERIES C PREFERRED:
	  	 	8,663,634	 
		  	  
	  
	 

  
 A-3 

SCHEDULE OF INVESTORS 

					
	
NAME AND ADDRESS
	  	SERIES D SHARES	 
	 OAK INVESTMENT PARTNERS XII, LIMITED
PARTNERSHIP
 901 Main Avenue, Suite 600

Norwalk, CT 06851
	  	 	9,519,276	 
		
	 DAG VENTURES IV-QP, L.P.

251 Lytton Avenue, Suite 200

Palo Alto, CA 94301

Tel: (650) 543-8180

Fax: (650) 328-2921
	  	 	1,377,508	 
		
	 DAG VENTURES IV, L.P.

251 Lytton Avenue, Suite 200

Palo Alto, CA 94301

Tel: (650) 543-8180

Fax: (650) 328-2921
	  	 	145,576	 
		
	 BENCHMARK CAPITAL PARTNERS V, L.P.

2965 Woodside Road

Woodside, CA 94062

Attn: Steve Spurlock
	  	 	3,046,168	 
		
	 THOMAS HO LEE, TRUSTEE
OF THE TXL REVOCABLE TRUST
 1
Hawthorne Street, 23D
 San Francisco, CA 94105
	  	 	95,192	 
		
	 SHARON A. KNIGHT 1993 TRUST

4315 21st Street

San Francisco, CA 94114
	  	 	95,192	 
		
	 TOTAL SERIES D PREFERRED:
	  	 	14,278,912	 
		  	  
	  
	 

  
 A-4 

SCHEDULE OF INVESTORS 

					
	
NAME AND ADDRESS
	  	SERIES E SHARES	 
	 MAVERICK FUND, L.D.C.

300 Crescent Court, Suite 1850

Dallas, TX 75201

Tel: (214)880-4040

Fax: (214)880-4042
	  	 	3,064,975	 
		
	 MAVERICK FUND USA, LTD.

300 Crescent Court, Suite 1850

Dallas, TX 75201

Tel: (214)880-4040

Fax: (214)880-4042
	  	 	1,724,781	 
		
	 MAVERICK HOLDINGS L, LLC

300 Crescent Court, Suite 1850

Dallas, TX 75201

Tel: (214)880-4040

Fax: (214)880-4042
	  	 	1,415,256	 
		
	 OAK INVESTMENT PARTNERS X II, LIMITED
PARTNERSHIP
 901 Main Avenue, Suite 600

Norwalk, CT 06851
	  	 	4,152,698	 
		
	 BENCHMARK CAPITAL PARTNERS V, L.P.

2965 Woodside Road

Woodside, CA 94062

Attn: Steve Spurlock
	  	 	1,358,786	 
		
	 DAG VENTURES IV-QP, L.P.

251 Lytton Avenue, Suite 200

Palo Alto, CA 94301

Tel: (650) 543-8180

Fax: (650) 328-2921
	  	 	627,242	 
		
	 DAG VENTURES IV, L.P.

251 Lytton Avenue, Suite 200

Palo Alto, CA 94301

Tel: (650) 543-8180

Fax: (650) 328-2921
	  	 	66,287	 
		
	 TOTAL SERIES E PREFERRED:
	  	 	12,410,025	 

  
 A-5 

SCHEDULE OF INVESTORS 

					
	

NAME AND ADDRESS
	  	SERIES F SHARES	 
	 MAVERICK FUND, L.D.C.

300 Crescent Court, Suite 1850

Dallas, TX 75201

Tel: (214)880-4040

Fax: (214)880-4042
	  	 	113,316	 
		
	 MAVERICK FUND USA, LTD.

300 Crescent Court, Suite 1850

Dallas, TX 75201

Tel: (214)880-4040

Fax: (214)880-4042
	  	 	97,501	 
		
	 MAVERICK HOLDINGS L, LLC

300 Crescent Court, Suite 1850

Dallas, TX 75201

Tel: (214)880-4040

Fax: (214)880-4042
	  	 	381,243	 
		
	 OAK INVESTMENT PARTNERS XII, LIMITED
PARTNERSHIP
 901 Main Avenue, Suite 600

Norwalk, CT 06851
	  	 	1,304,526	 
		
	 BENCHMARK CAPITAL PARTNERS V, L.P.

2965 Woodside Road

Woodside, CA 94062

Attn: Steve Spurlock
	  	 	1,325,406	 
		
	 DAG VENTURES IV-QP, L.P.

251 Lytton Avenue, Suite 200

Palo Alto, CA 94301

Tel: (650) 543-8180

Fax: (650) 328-2921
	  	 	611,832	 
		
	 DAG VENTURES IV, L.P.

251 Lytton Avenue, Suite 200

Palo Alto, CA 94301

Tel: (650) 543-8180

Fax: (650) 328-2921
	  	 	64,658	 
		
	 GV 2013, L.P.

Attn: GV Legal Department

1600 Amphitheatre Parkway

Mountain View, CA 94043

Facsimile: 650-887-1790

With a copy to (which shall not constitute notice):

Email: notice@gv.com
	  	 	7,796,967	 
		
	 TOTAL SERIES F PREFERRED:
	  	 	11,695,449	 

  
 A-6 

SCHEDULE OF INVESTORS 

					
	
NAME AND ADDRESS
	  	SERIES G SHARES	 
	 REDMILE CAPITAL OFFSHORE FUND II,
LTD.
 Letterman Digital Arts Center

One Letterman Drive, Building D, Suite D3-700

San Francisco, CA 94129
	  	 	759,209	 
		
	 REDMILE STRATEGIC MASTER FUND,
L.P.
 Letterman Digital Arts Center

One Letterman Drive, Building D, Suite D3-700

San Francisco, CA 94129
	  	 	367,837	 
		
	 REDMILE PRIVATE INVESTMENTS I, LP

Letterman Digital Arts Center

One Letterman Drive, Building D, Suite D3-700

San Francisco, CA 94129
	  	 	659,574	 
		
	 REDMILE PRIVATE INVESTMENTS I
AFFILIATES, LP
 Letterman Digital Arts Center

One Letterman Drive, Building D, Suite D3-700

San Francisco, CA 94129
	  	 	491,007	 
		
	 FIDELITY SELECT PORTFOLIOS: HEALTH
CARE PORTFOLIO
 Brown Brothers Harriman & Co.

525 Washington Blvd

Jersey City NJ 07310

Attn: Michael Lerman 15th Floor

Corporate Actions

Email: michael.lerman@bbh.com

Fax number: 617 772-2418
	  	 	1,639,892	 
		
	 FIDELITY SELECT PORTFOLIOS: MEDICAL EQUIPMENT
AND SYSTEMS PORTFOLIO
 Brown Brothers Harriman & Co.

525 Washington Blvd

Jersey City NJ 07310

Attn: Michael Lerman 15th Floor

Corporate Actions

Email: michael.lerman@bbh.com

Fax number: 617 772-2418
	  	 	455,526	 
		
	 FIDELITY CENTRAL INVESTMENT PORTFOLIOS LLC: FIDELITY
HEALTH CARE CENTRAL FUND
 M. Gardiner &
Co
 c/o JPMorgan Chase Bank, N.A

P.O. Box 35308

Newark, NJ 07101-8006

Email: Fidelity.crcs@jpmorgan.com

Jpmorganinformation.services@jpmorgan.com

Fax number: 469-477-1510
	  	 	438,101	 

  
 A-7 

SCHEDULE OF INVESTORS 

					
	
NAME AND ADDRESS
	  	SERIES G SHARES	 
	 FIDELITY ADVISOR SERIES VII: FIDELITY
ADVISOR HEALTH CARE FUND
 M. Gardiner &
Co
 c/o JPMorgan Chase Bank, N.A

P.O. Box 35308

Newark, NJ 07101-8006

Email: Fidelity.crcs@jpmorgan.com

Jpmorganinformation.services@jpmorgan.com

Fax number: 469-477-1510
	  	 	322,145	 
		
	 VARIABLE INSURANCE PRODUCTS FUND IV:
HEALTH CARE PORTFOLIO
 M. Gardiner & Co

c/o JPMorgan Chase Bank, N.A

P.O. Box 35308

Newark, NJ 07101-8006

Email: Fidelity.crcs@jpmorgan.com

Jpmorganinformation.services@jpmorgan.com

Fax number: 469-477-1510
	  	 	181,172	 
		
	 MAVERICK HOLDINGS L, LLC

300 Crescent Court, Suite 1850

Dallas, TX 75201

Tel: (214)880-4040

Fax: (214)880-4042
	  	 	98,371	 
		
	 OAK INVESTMENT PARTNERS XII, LIMITED
PARTNERSHIP
 901 Main Avenue, Suite 600

Norwalk, CT 06851
	  	 	216,748	 
		
	 BENCHMARK CAPITAL PARTNERS V, L.P.

2965 Woodside Road

Woodside, CA 94062

Attn: Steve Spurlock
	  	 	220,217	 
		
	 DAG VENTURES IV-QP, L.P.

251 Lytton Avenue, Suite 200

Palo Alto, CA 94301

Tel: (650) 543-8180

Fax: (650) 328-2921
	  	 	101,656	 
		
	 DAG VENTURES IV, L.P.

251 Lytton Avenue, Suite 200

Palo Alto, CA 94301

Tel: (650) 543-8180

Fax: (650) 328-2921
	  	 	10,743	 

  
 A-8 

SCHEDULE OF INVESTORS 

					
	
NAME AND ADDRESS
	  	SERIES G SHARES	 
	 GV 2013, L.P.

Attn: GV Legal Department

1600 Amphitheatre Parkway

Mountain View, CA 94043

Facsimile: 650-887-1790

 
 With a copy to (which shall not
constitute notice):
 Email: notice@gv.com
	  	 	111,472	 
		
	 ALLEN PARTNERS FUND I LP

c/o Allen & Company LLC

711 Fifth Avenue

New York, NY 10022

Attn: Peter DiLorio
	  	 	72,124	 
		
	 JOHN KOSKI

c/o Allen & Company LLC

711 Fifth Avenue

New York, NY 10022
	  	 	1,898	 
		
	 ROBERT LOWE

c/o Allen & Company LLC

711 Fifth Avenue

New York, NY 10022
	  	 	1,898	 
		
	 DIGNITY HEALTH

185 Berry Street, Suite 300

San Francisco, CA 94107

Attn: Lisa Zuckerman
	  	 	455,525	 
		
	 TOTAL SERIES G PREFERRED:
	  	 	6,605,115	 

  
 A-9 

SCHEDULE OF INVESTORS 

					
	
NAME AND ADDRESS
	  	SERIES H SHARES	 
	 PEG DIGITAL GROWTH FUND II L.P.

Lawrence Unrein

JP Morgan Asset Management

Private Equity Group

320 Park Avenue - 15th Floor

NY1-U016

New York, NY 10022

Email: lawrence.m.unrein@jpmorgan.com
  

and:
  

Tyler Jayroe

JP Morgan Asset Management

Private Equity Group

320 Park Avenue - 15th Floor

NY1-U016

New York, NY 10022

Email: tyler.a.jayroe@jpmorgan.com
  

With a copy to (which shall not constitute notice):

Marc A. Persily

Proskauer Rose LLP

Eleven Times Square

New York, NY 10036-8299

Email: mpersily@proskauer.com
	  	 	5,383,180	 

  
 A-10 

SCHEDULE OF INVESTORS 

					
	
NAME AND ADDRESS
	  	SERIES H SHARES	 
	 AARP INNOVATION FUND L.P.

Lawrence Unrein

JP Morgan Asset Management

Private Equity Group

320 Park Avenue - 15th Floor

NY1-U016

New York, NY 10022

Email: lawrence.m.unrein@jpmorgan.com
  

and:
  

Tyler Jayroe

JP Morgan Asset Management

Private Equity Group

320 Park Avenue - 15th Floor

NY1-U016

New York, NY 10022

Email: tyler.a.jayroe@jpmorgan.com
  

With a copy to (which shall not constitute notice):

Marc A. Persily

Proskauer Rose LLP

Eleven Times Square

New York, NY 10036-8299

Email: mpersily@proskauer.com
	  	 	343,607	 
		
	 LANSDOWNE DEVELOPED MARKETS MASTER FUND
LIMITED
 c/o Lansdowne Partners (UK) LLP

15 Davies Street

London W1K 3AG

United Kingdom

Tel: +44 (0) 20 7290 5500

Email: PE@LansdownePartners.com
  

With a copy to:

Compliance@LansdownePartners.com
	  	 	1,145,358	 
		
	 H. BARTON CO-INVEST FUND II,
LLC
 135 Main Street, Suite 850

San Francisco, CA 94105

Email: harris@bartonam.com, kyle@bartonam.com
	  	 	114,536	 
		
	 FAVREAU 2008 TRUST, DTD
4-10-2008
 c/o Shephard McIlwee
Tinglof
 9200 Sunset Boulevard, Penthouse 22

Los Angeles, CA 90069

Attn: Jon Favreau
	  	 	114,536	 

  
 A-11 

SCHEDULE OF INVESTORS 

					
	
NAME AND ADDRESS
	  	SERIES H SHARES	 
	 OAK INVESTMENT PARTNERS XII, LIMITED
PARTNERSHIP
 901 Main Avenue, Suite 600

Norwalk, CT 06851
	  	 	52,281	 
		
	 GV 2013, L.P.

Attn: GV Legal Department

1600 Amphitheatre Parkway

Mountain View, CA 94043

Facsimile: 650-887-1790

 
 With a copy to (which shall not
constitute notice):
 Email: notice@gv.com
	  	 	28,634	 
		
	 MAVERICK HOLDINGS L, LLC

300 Crescent Court, Suite 1850

Dallas, TX 75201

Tel: (214)880-4040

Fax: (214)880-4042
	  	 	28,634	 
		
	 REDMILE CAPITAL OFFSHORE FUND II,
LTD.
 Letterman Digital Arts Center

One Letterman Drive, Building D, Suite D3-700

San Francisco, CA 94129
	  	 	76,357	 
		
	 REDMILE STRATEGIC MASTER FUND,
L.P.
 Letterman Digital Arts Center

One Letterman Drive, Building D, Suite D3-700

San Francisco, CA 94129
	  	 	36,995	 
		
	 REDMILE PRIVATE INVESTMENTS I, LP

Letterman Digital Arts Center

One Letterman Drive, Building D, Suite D3-700

San Francisco, CA 94129
	  	 	66,337	 
		
	 REDMILE PRIVATE INVESTMENTS I
AFFILIATES, LP
 Letterman Digital Arts Center

One Letterman Drive, Building D, Suite D3-700

San Francisco, CA 94129
	  	 	49,383	 
		
	 DIGNITY HEALTH

185 Berry Street, Suite 300

San Francisco, CA 94107
	  	 	4,276	 
		
	 ALLEN PARTNERS FUND I LP

c/o Allen & Company LLC

711 Fifth Avenue

New York, NY 10022

Attn: Peter DiLorio
	  	 	677	 

  
 A-12 

SCHEDULE OF INVESTORS 

					
	
NAME AND ADDRESS
	  	SERIES H SHARES	 
	 JOHN KOSKI

c/o Allen & Company LLC

711 Fifth Avenue

New York, NY 10022
	  	 	18	 
		
	 ROBERT LOWE

c/o Allen & Company LLC

711 Fifth Avenue

New York, NY 10022
	  	 	18	 
		  	  
	  
	 
	 TOTAL SERIES H PREFERRED:
	  	 	7,444,827	 
		  	  
	  
	 

  
 A-13 

SCHEDULE OF INVESTORS 

					
	
NAME AND ADDRESS
	  	SERIES I SHARES	 
	 CARLYLE PARTNERS VII HOLDINGS, L.P.

520 Madison Avenue

New York, NY 10022
	  	 	17,699,115	 
		  	  
	  
	 
	 TOTAL:
	  	 	17,699,115	 
		  	  
	  
	 

  
 A-14 

SCHEDULE OF INVESTORSEX-10.4

 Exhibit 10.4 

1LIFE HEALTHCARE, INC. 

2017 EQUITY INCENTIVE PLAN 

ADOPTED BY THE BOARD OF DIRECTORS: February 9, 2017 

APPROVED BY THE STOCKHOLDERS: February 17, 2017 

ADOPTED BY THE BOARD OF DIRECTORS: September 14, 2017 

APPROVED BY THE STOCKHOLDERS: November 20, 2017 

AMENDED BY THE BOARD OF DIRECTORS: November 21, 2019 

APPROVED BY THE STOCKHOLDERS: January 15, 2020 

TERMINATION DATE: February 8, 2027 
  

	1.	 GENERAL. 

(a) Successor to and Continuation of Prior Plan. The Plan is intended as the successor to and continuation of the Company’s
Amended 2007 Equity Incentive Plan (the “Prior Plan”). Following the Effective Date, no additional stock awards will be granted under the Prior Plan. Any shares remaining available for issuance pursuant to the exercise of
options or issuance or settlement of stock awards under the Prior Plan as of the Effective Date (the “Prior Plan’s Available Reserve”) will become available for issuance pursuant to Stock
Awards granted hereunder. From and after the Effective Date, all outstanding stock awards granted under the Prior Plan will remain subject to the terms of the Prior Plan; provided, however, any shares subject to outstanding stock awards
granted under the Prior Plan that (i) expire or terminate for any reason prior to exercise or settlement; (ii) are forfeited, cancelled or otherwise returned to the Company because of the failure to meet a contingency or condition required
to vest such shares; or (iii) are reacquired, withheld (or not issued) to satisfy a tax withholding obligation in connection with an award or to satisfy the purchase price or exercise price of a stock award (the “Returning
Shares”) will become available for issuance pursuant to Awards granted hereunder. All Awards granted on or after the Effective Date of this Plan will be subject to the terms of this Plan. 

(b) Eligible Stock Award Recipients. Employees, Directors and Consultants are eligible to receive Stock Awards. 

(c) Available Stock Awards. The Plan provides for the grant of the following types of Stock Awards: (i) Incentive Stock
Options, (ii) Nonstatutory Stock Options, (iii) Stock Appreciation Rights, (iv) Restricted Stock Awards, (v) Restricted Stock Unit Awards and (vi) Other Stock Awards. 

(d) Purpose. The Plan, through the grant of Stock Awards, is intended to help the Company secure and retain the services of
eligible award recipients, provide incentives for such persons to exert maximum efforts for the success of the Company and any Affiliate and provide a means by which the eligible recipients may benefit from increases in value of the Common Stock.

  

	2.	 ADMINISTRATION. 

(a) Administration by the Board. The Board will administer the Plan. The Board may delegate administration of the Plan to a Committee or
Committees, as provided in Section 2(c). 
 (b) Powers of the Board. The Board will have the power, subject to, and within the
limitations of, the express provisions of the Plan: 

  
 1. 

 (i) To determine (A) who will be granted Stock Awards; (B) when and how
each Stock Award will be granted; (C) what type of Stock Award will be granted; (D) the provisions of each Stock Award (which need not be identical), including when a person will be permitted to exercise or otherwise receive cash or Common
Stock under the Stock Award; (E) the number of shares of Common Stock subject to, or the cash value of, a Stock Award; and (F) the Fair Market Value applicable to a Stock Award. 

(ii) To construe and interpret the Plan and Stock Awards granted under it, and to establish, amend and revoke rules and regulations for
administration of the Plan and Stock Awards. The Board, in the exercise of these powers, may correct any defect, omission or inconsistency in the Plan or in any Stock Award Agreement, in a manner and to the extent it will deem necessary or expedient
to make the Plan or Stock Award fully effective. 
 (iii) To settle all controversies regarding the Plan and Stock Awards granted
under it. 
 (iv) To accelerate, in whole or in part, the time at which a Stock Award may be exercised or vest (or the time at which
cash or shares of Common Stock may be issued in settlement thereof). 
 (v) To suspend or terminate the Plan at any time. Except as
otherwise provided in the Plan or a Stock Award Agreement, suspension or termination of the Plan will not impair a Participant’s rights under the Participant’s then-outstanding Stock Award without the Participant’s written consent
except as provided in subsection (viii) below. 
 (vi) To amend the Plan in any respect the Board deems necessary or advisable,
including, without limitation, by adopting amendments relating to Incentive Stock Options and certain nonqualified deferred compensation under Section 409A of the Code and/or bringing the Plan or Stock Awards granted under the Plan into
compliance with the requirements for Incentive Stock Options or ensuring that they are exempt from, or compliant with, the requirements for nonqualified deferred compensation under Section 409A of the Code, subject to the limitations, if any,
of applicable law. If required by applicable law or listing requirements, and except as provided in Section 9(a) relating to Capitalization Adjustments, the Company will seek stockholder approval of any amendment of the Plan that
(A) materially increases the number of shares of Common Stock available for issuance under the Plan, (B) materially expands the class of individuals eligible to receive Stock Awards under the Plan, (C) materially increases the
benefits accruing to Participants under the Plan, (D) materially reduces the price at which shares of Common Stock may be issued or purchased under the Plan, (E) materially extends the term of the Plan, or (F) materially expands the
types of Stock Awards available for issuance under the Plan. Except as otherwise provided in the Plan or a Stock Award Agreement, no amendment of the Plan will materially impair a Participant’s rights under an outstanding Stock Award without
the Participant’s written consent. 
 (vii) To submit any amendment to the Plan for stockholder approval, including, but not
limited to, amendments to the Plan intended to satisfy the requirements of Section 422 of the Code regarding Incentive Stock Options. 

(viii) To approve forms of Stock Award Agreements for use under the Plan and to amend the terms of any one or more Stock Awards,
including, but not limited to, amendments to provide terms more favorable to the Participant than previously provided in the Stock Award Agreement, subject to any specified limits in the Plan that are not subject to Board discretion; provided
however, that a Participant’s rights under any Stock Award will not be impaired by any such amendment unless (A) the Company 

  
 2. 

 
requests the consent of the affected Participant, and (B) such Participant consents in writing. Notwithstanding the foregoing, (1) a Participant’s rights will not be deemed to have
been impaired by any such amendment if the Board, in its sole discretion, determines that the amendment, taken as a whole, does not materially impair the Participant’s rights, and (2) subject to the limitations of applicable law, if any,
the Board may amend the terms of any one or more Stock Awards without the affected Participant’s consent (A) to maintain the qualified status of the Stock Award as an Incentive Stock Option under Section 422 of the Code; (B) to
change the terms of an Incentive Stock Option, if such change results in impairment of the Stock Award solely because it impairs the qualified status of the Stock Award as an Incentive Stock Option under Section 422 of the Code; (C) to
clarify the manner of exemption from, or to bring the Stock Award into compliance with, Section 409A of the Code; or (D) to comply with other applicable laws. 

(ix) Generally, to exercise such powers and to perform such acts as the Board deems necessary or expedient to promote the best interests
of the Company and that are not in conflict with the provisions of the Plan or Stock Awards. 
 (x) To adopt such procedures and sub-plans as are necessary or appropriate to permit participation in the Plan by Employees, Directors or Consultants who are foreign nationals or employed outside the United States (provided that Board approval will
not be necessary for immaterial modifications to the Plan or any Stock Award Agreement that are required for compliance with the laws of the relevant foreign jurisdiction). 

(xi) To effect, with the consent of any adversely affected Participant, (A) the reduction of the exercise, purchase or strike price
of any outstanding Stock Award; (B) the cancellation of any outstanding Stock Award and the grant in substitution therefor of a new (1) Option or SAR, (2) Restricted Stock Award, (3) Restricted Stock Unit Award, (4) Other
Stock Award, (5) cash and/or (6) other valuable consideration determined by the Board, in its sole discretion, with any such substituted award (x) covering the same or a different number of shares of Common Stock as the cancelled
Stock Award and (y) granted under the Plan or another equity or compensatory plan of the Company; or (C) any other action that is treated as a repricing under generally accepted accounting principles. 

(c) Delegation to Committee. The Board may delegate some or all of the administration of the Plan to a Committee or Committees. If
administration of the Plan is delegated to a Committee, the Committee will have, in connection with the administration of the Plan, the powers theretofore possessed by the Board that have been delegated to the Committee, including the power to
delegate to a subcommittee of the Committee any of the administrative powers the Committee is authorized to exercise (and references in this Plan to the Board will thereafter be to the Committee or subcommittee, as applicable). Any delegation of
administrative powers will be reflected in resolutions, not inconsistent with the provisions of the Plan, adopted from time to time by the Board or Committee (as applicable). The Board may retain the authority to concurrently administer the Plan
with the Committee and may, at any time, revest in the Board some or all of the powers previously delegated. 
 (d)
Delegation to an Officer. The Board may delegate to one or more Officers the authority to do one or both of the following: (i) designate Employees who are not Officers to be recipients of Options and SARs (and, to the extent
permitted by applicable law, other Stock Awards) and, to the extent permitted by applicable law, the terms of such Stock Awards, and (ii) determine the number of shares of Common Stock to be subject to such Stock Awards granted to such
Employees; provided, however, that the Board resolutions regarding such delegation will specify the total number of shares of Common Stock that may be subject to the Stock Awards granted by such Officer and that such Officer may not grant a
Stock Award to himself or herself. Any such Stock Awards will be granted on the form of Stock Award Agreement most 

  
 3. 

 
recently approved for use by the Committee or the Board, unless otherwise provided in the resolutions approving the delegation authority. The Board may not delegate authority to an Officer who is
acting solely in the capacity of an Officer (and not also as a Director) to determine the Fair Market Value pursuant to Section 13(t) below.  

(e) Effect of Board’s Decision. All determinations, interpretations and constructions made by the Board in
good faith will not be subject to review by any person and will be final, binding and conclusive on all persons. 
 (f)
Arbitration. Any dispute or claim concerning any Stock Awards granted (or not granted) pursuant to the Plan or any disputes or claims relating to or arising out of the Plan shall be fully, finally and exclusively resolved by binding and
confidential arbitration conducted pursuant to the Commercial Arbitration Rules of the American Arbitration Association the rules of Judicial Arbitration and Mediation Services, Inc. (“JAMS”) in California. The Company shall pay all
arbitration fees. In addition to any other relief, the arbitrator may award to the prevailing party recovery of its attorneys’ fees and costs. By accepting a Stock Award, Participants and the Company waive their respective rights to have any
such disputes or claims tried by a judge or jury. 
  

	3.	 SHARES SUBJECT TO THE PLAN.

 (a) Share Reserve. 

(i) Subject to Section 9(a) relating to Capitalization Adjustments, the aggregate number of shares of Common Stock that may be
issued pursuant to Stock Awards from and after the Effective Date will not exceed 34,822,123 shares (the “Share Reserve”), which number is the sum of (i) the number of shares subject to the Prior Plan’s Available
Reserve, (ii) an additional 21,607,000 new shares, plus (iii) an additional number of shares in an amount not to exceed 11,656,735 shares (which number consists of the Returning Shares, if any, as such shares become available from time to
time). 
 (ii) For clarity, the Share Reserve in this Section 3(a) is a limitation on the number of shares of Common Stock that
may be issued pursuant to the Plan. Accordingly, this Section 3(a) does not limit the granting of Stock Awards except as provided in Section 7(a). 

(b) Reversion of Shares to the Share Reserve. If a Stock Award or any portion thereof (i) expires or otherwise terminates
without all of the shares covered by such Stock Award having been issued or (ii) is settled in cash (i.e., the Participant receives cash rather than stock), such expiration, termination or settlement will not reduce (or otherwise offset)
the number of shares of Common Stock that may be available for issuance under the Plan. If any shares of Common Stock issued pursuant to a Stock Award are forfeited back to or repurchased by the Company because of the failure to meet a contingency
or condition required to vest such shares in the Participant, then the shares that are forfeited or repurchased will revert to and again become available for issuance under the Plan. Any shares reacquired by the Company in satisfaction of tax
withholding obligations on a Stock Award or as consideration for the exercise or purchase price of a Stock Award will again become available for issuance under the Plan. 

(c) Incentive Stock Option Limit. Subject to the Share Reserve and Section 9(a) relating to Capitalization
Adjustments, the aggregate maximum number of shares of Common Stock that may be issued pursuant to the exercise of Incentive Stock Options will be a number of shares of Common Stock equal to three multiplied by the Share Reserve. 

  
 4. 

 (d) Source of Shares. The stock issuable under the Plan will be shares of authorized
but unissued or reacquired Common Stock, including shares repurchased by the Company on the open market or otherwise. 
  

	4.	 ELIGIBILITY. 

(a) Eligibility for Specific Stock Awards. Incentive Stock Options may be granted only to employees of the Company or a “parent
corporation” or “subsidiary corporation” thereof (as such terms are defined in Sections 424(e) and 424(f) of the Code). Stock Awards other than Incentive Stock Options may be granted to Employees, Directors and Consultants;
provided, however, that Stock Awards may not be granted to Employees, Directors and Consultants who are providing Continuous Service only to any “parent” of the Company, as such term is defined in Rule 405, unless (i) the
stock underlying such Stock Awards is treated as “service recipient stock” under Section 409A of the Code (for example, because the Stock Awards are granted pursuant to a corporate transaction such as a spin off transaction), (ii) the
Company, in consultation with its legal counsel, has determined that such Stock Awards are otherwise exempt from Section 409A of the Code, or (iii) the Company, in consultation with its legal counsel, has determined that such Stock Awards
comply with the distribution requirements of Section 409A of the Code. 
 (b) Ten Percent Stockholders. A Ten Percent
Stockholder will not be granted an Incentive Stock Option unless the exercise price of such Option is at least 110% of the Fair Market Value on the date of grant and the Option is not exercisable after the expiration of five years from the date
of grant. 
 (c) Consultants. A Consultant will not be eligible for the grant of a Stock Award if, at the time of grant,
either the offer or sale of the Company’s securities to such Consultant is not exempt under Rule 701 because of the nature of the services that the Consultant is providing to the Company, because the Consultant is not a natural person, or
because of any other provision of Rule 701, unless the Company determines that such grant need not comply with the requirements of Rule 701 and will satisfy another exemption under the Securities Act as well as comply with the securities
laws of all other relevant jurisdictions. 
  

	5.	 PROVISIONS RELATING TO OPTIONS
AND STOCK APPRECIATION RIGHTS. 

 Each Option or SAR will
be in such form and will contain such terms and conditions as the Board deems appropriate. All Options will be separately designated Incentive Stock Options or Nonstatutory Stock Options at the time of grant, and, if certificates are issued, a
separate certificate or certificates will be issued for shares of Common Stock purchased on exercise of each type of Option. If an Option is not specifically designated as an Incentive Stock Option, or if an Option is designated as an Incentive
Stock Option but some portion or all of the Option fails to qualify as an Incentive Stock Option under the applicable rules, then the Option (or portion thereof) will be a Nonstatutory Stock Option. The provisions of separate Options or SARs need
not be identical; provided, however, that each Stock Award Agreement will conform to (through incorporation of provisions hereof by reference in the applicable Stock Award Agreement or otherwise) the substance of each of the following
provisions: 
 (a) Term. Subject to the provisions of Section 4(b) regarding Ten Percent Stockholders, no Option or SAR will be
exercisable after the expiration of 10 years from the date of its grant or such shorter period specified in the Stock Award Agreement. 

  
 5. 

 (b) Exercise Price. Subject to the provisions of Section 4(b) regarding Ten
Percent Stockholders, the exercise or strike price of each Option or SAR will be not less than 100% of the Fair Market Value of the Common Stock subject to the Option or SAR on the date the Stock Award is granted. Notwithstanding the foregoing, an
Option or SAR may be granted with an exercise or strike price lower than 100% of the Fair Market Value of the Common Stock subject to the Stock Award if such Stock Award is granted pursuant to an assumption of or substitution for another option or
stock appreciation right pursuant to a Corporate Transaction and in a manner consistent with the provisions of Section 409A of the Code and, if applicable, Section 424(a) of the Code. Each SAR will be denominated in shares of Common Stock
equivalents. 
 (c) Purchase Price for Options. The purchase price of Common Stock acquired pursuant to the exercise of an
Option may be paid, to the extent permitted by applicable law and as determined by the Board in its sole discretion, by any combination of the methods of payment set forth below. The Board will have the authority to grant Options that do not permit
all of the following methods of payment (or otherwise restrict the ability to use certain methods) and to grant Options that require the consent of the Company to use a particular method of payment. The permitted methods of payment are as follows:

 (i) by cash, check, bank draft or money order payable to the Company; 

(ii) pursuant to a program developed under Regulation T as promulgated by the Federal Reserve Board that, prior to the issuance of
the stock subject to the Option, results in either the receipt of cash (or check) by the Company or the receipt of irrevocable instructions to pay the aggregate exercise price to the Company from the sales proceeds; 

(iii) by delivery to the Company (either by actual delivery or attestation) of shares of Common Stock; 

(iv) if an Option is a Nonstatutory Stock Option, by a “net exercise” arrangement pursuant to which the Company will reduce
the number of shares of Common Stock issuable upon exercise by the largest whole number of shares with a Fair Market Value that does not exceed the aggregate exercise price; provided, however, that the Company will accept a cash or other
payment from the Participant to the extent of any remaining balance of the aggregate exercise price not satisfied by such reduction in the number of whole shares to be issued. Shares of Common Stock will no longer be subject to an Option and will
not be exercisable thereafter to the extent that (A) shares issuable upon exercise are used to pay the exercise price pursuant to the “net exercise,” (B) shares are delivered to the Participant as a result of such exercise, and
(C) shares are withheld to satisfy tax withholding obligations; 
 (v) according to a deferred payment or similar arrangement
with the Optionholder; provided, however, that interest will compound at least annually and will be charged at the minimum rate of interest necessary to avoid (A) the imputation of interest income to the Company and compensation income
to the Optionholder under any applicable provisions of the Code, and (B) the classification of the Option as a liability for financial accounting purposes; or 

(vi) in any other form of legal consideration that may be acceptable to the Board and specified in the applicable Stock Award Agreement.

 (d) Exercise and Payment of a SAR. To exercise any outstanding SAR, the Participant must provide written notice of exercise
to the Company in compliance with the provisions of the Stock Appreciation Right Agreement evidencing such SAR. The appreciation distribution payable on the exercise of a SAR will be not greater than an amount equal to the excess of (A) the
aggregate Fair Market Value (on the date of the exercise of the SAR) of a number of shares of Common Stock equal to the number of 

  
 6. 

 
Common Stock equivalents in which the Participant is vested under such SAR, and with respect to which the Participant is exercising the SAR on such date, over (B) the aggregate strike price
of the number of Common Stock equivalents with respect to which the Participant is exercising the SAR on such date. The appreciation distribution may be paid in Common Stock, in cash, in any combination of the two or in any other form of
consideration, as determined by the Board and contained in the Stock Award Agreement evidencing such SAR. 
 (e) Transferability of
Options and SARs. The Board may, in its sole discretion, impose such limitations on the transferability of Options and SARs as the Board will determine. In the absence of such a determination by the Board to the contrary, the following
restrictions on the transferability of Options and SARs will apply: 
 (i) Restrictions on Transfer. An Option or SAR will not be
transferable except by will or by the laws of descent and distribution (or pursuant to subsections (ii) and (iii) below), and will be exercisable during the lifetime of the Participant only by the Participant. The Board may permit transfer of
the Option or SAR in a manner that is not prohibited by applicable tax and securities laws. Except as explicitly provided in the Plan, neither an Option nor a SAR may be transferred for consideration. 

(ii) Domestic Relations Orders. Subject to the approval of the Board or a duly authorized Officer, an Option or SAR may be transferred
pursuant to the terms of a domestic relations order, official marital settlement agreement or other divorce or separation instrument as permitted by Treasury Regulation 1.421-1(b)(2). If an Option is an
Incentive Stock Option, such Option may be deemed to be a Nonstatutory Stock Option as a result of such transfer. 
 (f) Vesting
Generally. The total number of shares of Common Stock subject to an Option or SAR may vest and therefore become exercisable in periodic installments that may or may not be equal. The Option or SAR may be subject to such other terms and
conditions on the time or times when it may or may not be exercised (which may be based on the satisfaction of performance goals or other criteria) as the Board may deem appropriate. The vesting provisions of individual Options or SARs may vary. The
provisions of this Section 5(f) are subject to any Option or SAR provisions governing the minimum number of shares of Common Stock as to which an Option or SAR may be exercised. 

(g) Termination of Continuous Service. Except as otherwise provided in the applicable Stock Award Agreement or other agreement between
the Participant and the Company, if a Participant’s Continuous Service terminates (other than for Cause and other than upon the Participant’s death or Disability), the Participant may exercise his or her Option or SAR (to the extent that
the Participant was entitled to exercise such Stock Award as of the date of termination of Continuous Service) within the period of time ending on the earlier of (i) the date three months following the termination of the Participant’s
Continuous Service (or such longer or shorter period specified in the applicable Stock Award Agreement, which period will not be less than 30 days if necessary to comply with applicable laws unless such termination is for Cause) and
(ii) the expiration of the term of the Option or SAR as set forth in the Stock Award Agreement. If, after termination of Continuous Service, the Participant does not exercise his or her Option or SAR (as applicable) within the applicable time
frame, the Option or SAR will terminate. 
 (h) Extension of Termination Date. If the exercise of an Option or SAR following
the termination of the Participant’s Continuous Service (other than for Cause and other than upon the Participant’s death or Disability) would be prohibited at any time solely because the issuance of shares of Common Stock would violate
the registration requirements under the Securities Act, then the Option or SAR will terminate on the earlier of (i) the expiration of a total period of time (that need not be consecutive) 

  
 7. 

 
equal to the applicable post-termination exercise period after the termination of the Participant’s Continuous Service during which the exercise of the Option or SAR would not be in
violation of such registration requirements, and (ii) the expiration of the term of the Option or SAR as set forth in the applicable Stock Award Agreement. In addition, unless otherwise provided in a Participant’s Stock Award Agreement, if
the sale of any Common Stock received upon exercise of an Option or SAR following the termination of the Participant’s Continuous Service (other than for Cause) would violate the Company’s insider trading policy, then the Option or SAR
will terminate on the earlier of (i) the expiration of the period of time (that need not be consecutive) equal to the applicable post-termination exercise period after the termination of the Participant’s Continuous Service during which
the sale of the Common Stock received upon exercise of the Option or SAR would not be in violation of the Company’s insider trading policy, and (ii) the expiration of the term of the Option or SAR as set forth in the applicable Stock Award
Agreement. 
 (i) Disability of Participant. Except as otherwise provided in the applicable Stock Award Agreement
or other agreement between the Participant and the Company, if a Participant’s Continuous Service terminates as a result of the Participant’s Disability, the Participant may exercise his or her Option or SAR (to the extent that the
Participant was entitled to exercise such Option or SAR as of the date of termination of Continuous Service), but only within such period of time ending on the earlier of (i) the date 12 months following such termination of Continuous
Service (or such longer or shorter period specified in the Stock Award Agreement, which period will not be less than six months if necessary to comply with applicable laws unless such termination is for Cause), and (ii) the expiration of
the term of the Option or SAR as set forth in the Stock Award Agreement. If, after termination of Continuous Service, the Participant does not exercise his or her Option or SAR within the applicable time frame, the Option or SAR (as applicable) will
terminate. 
 (j) Death of Participant. Except as otherwise provided in the applicable Stock Award Agreement or other agreement
between the Participant and the Company, if (i) a Participant’s Continuous Service terminates as a result of the Participant’s death, or (ii) the Participant dies within the period (if any) specified in the Stock Award Agreement
for exercisability after the termination of the Participant’s Continuous Service (for a reason other than death), then the Option or SAR may be exercised (to the extent the Participant was entitled to exercise such Option or SAR as of the date
of death) by the Participant’s estate, by a person who acquired the right to exercise the Option or SAR by bequest or inheritance or by a person designated to exercise the Option or SAR upon the Participant’s death, but only within the
period ending on the earlier of (i) the date 18 months following the date of death (or such longer or shorter period specified in the Stock Award Agreement, which period will not be less than six months if necessary to comply with
applicable laws unless such termination is for Cause), and (ii) the expiration of the term of such Option or SAR as set forth in the Stock Award Agreement. If, after the Participant’s death, the Option or SAR is not exercised within the
applicable time frame, the Option or SAR (as applicable) will terminate. 
 (k) Termination for Cause. Except as
explicitly provided otherwise in a Participant’s Stock Award Agreement or other individual written agreement between the Company or any Affiliate and the Participant, if a Participant’s Continuous Service is terminated for Cause, the
Option or SAR will terminate immediately upon such Participant’s termination of Continuous Service, and the Participant will be prohibited from exercising his or her Option or SAR from and after the date of such termination of Continuous
Service. 
 (l) Non-Exempt Employees. If an Option or SAR is granted to an Employee who is a non-exempt employee for purposes of the Fair Labor Standards Act of 1938, as amended, the Option or SAR will not be first exercisable for any shares of Common Stock until at least six months following the date of
grant of the Option or SAR (although the Stock Award may vest prior to such date). Consistent with the 

  
 8. 

 
provisions of the Worker Economic Opportunity Act, (i) if such non-exempt Employee dies or suffers a Disability, (ii) upon a Corporate
Transaction in which such Option or SAR is not assumed, continued, or substituted, (iii) upon a Change in Control, or (iv) upon the Participant’s retirement (as such term may be defined in the Participant’s Stock Award Agreement,
in another agreement between the Participant and the Company, or, if no such definition, in accordance with the Company’s then current employment policies and guidelines), the vested portion of any Options and SARs may be exercised earlier than
six months following the date of grant. The foregoing provision is intended to operate so that any income derived by a non-exempt employee in connection with the exercise or vesting of an Option or SAR will be
exempt from his or her regular rate of pay. To the extent permitted and/or required for compliance with the Worker Economic Opportunity Act to ensure that any income derived by a non-exempt employee in
connection with the exercise, vesting or issuance of any shares under any other Stock Award will be exempt from the employee’s regular rate of pay, the provisions of this Section 5(l) will apply to all Stock Awards and are hereby
incorporated by reference into such Stock Award Agreements. 
 (m) Early Exercise of Options. An Option may, but need not, include a
provision whereby the Optionholder may elect at any time before the Optionholder’s Continuous Service terminates to exercise the Option as to any part or all of the shares of Common Stock subject to the Option prior to the full vesting of the
Option. Subject to the “Repurchase Limitation” in Section 8(l), any unvested shares of Common Stock so purchased may be subject to a repurchase right in favor of the Company or to any other restriction the Board determines to be
appropriate. Provided that the “Repurchase Limitation” in Section 8(l) is not violated, the Company will not be required to exercise its repurchase right until at least six months (or such longer or shorter period of time
required to avoid classification of the Option as a liability for financial accounting purposes) have elapsed following exercise of the Option unless the Board otherwise specifically provides in the Option Agreement. 

(n) Right of Repurchase. Subject to the “Repurchase Limitation” in Section 8(l), the Option or SAR may include a
provision whereby the Company may elect to repurchase all or any part of the vested shares of Common Stock acquired by the Participant pursuant to the exercise of the Option or SAR. 

(o) Right of First Refusal. The Option or SAR may include a provision whereby the Company may elect to exercise a right of first
refusal following receipt of notice from the Participant of the intent to transfer all or any part of the shares of Common Stock received upon the exercise of the Option or SAR. Such right of first refusal will be subject to the
“Repurchase Limitation” in Section 8(l). Except as expressly provided in this Section 5(o) or in the Stock Award Agreement, such right of first refusal will otherwise comply with any applicable provisions of the bylaws of
the Company. 
  

	6.	 PROVISIONS OF STOCK AWARDS OTHER
THAN OPTIONS AND SARS. 

 (a) Restricted Stock
Awards. Each Restricted Stock Award Agreement will be in such form and will contain such terms and conditions as the Board will deem appropriate. To the extent consistent with the Company’s bylaws, at the Board’s election, shares of
Common Stock underlying a Restricted Stock Award may be (i) held in book entry form subject to the Company’s instructions until any restrictions relating to the Restricted Stock Award lapse; or (ii) evidenced by a certificate, which
certificate will be held in such form and manner as determined by the Board. The terms and conditions of Restricted Stock Award Agreements may change from time to time, and the terms and conditions of separate Restricted Stock Award Agreements need
not be identical. Each Restricted Stock Award Agreement will conform to (through incorporation of the provisions hereof by reference in the agreement or otherwise) the substance of each of the following provisions: 

  
 9. 

 (i) Consideration. A Restricted Stock Award may be awarded in consideration for
(A) cash, check, bank draft or money order payable to the Company, (B) past services to the Company or an Affiliate, or (C) any other form of legal consideration (including future services) that may be acceptable to the Board,
in its sole discretion, and permissible under applicable law. 
 (ii) Vesting. Subject to the “Repurchase Limitation”
in Section 8(l), shares of Common Stock awarded under the Restricted Stock Award Agreement may be subject to forfeiture to the Company in accordance with a vesting schedule to be determined by the Board. 

(iii) Termination of Participant’s Continuous Service. If a Participant’s Continuous Service terminates, the Company may
receive through a forfeiture condition or a repurchase right, any or all of the shares of Common Stock held by the Participant that have not vested as of the date of termination of Continuous Service under the terms of the Restricted Stock Award
Agreement. 
 (iv) Transferability. Rights to acquire shares of Common Stock under the Restricted Stock Award Agreement will be
transferable by the Participant only upon such terms and conditions as are set forth in the Restricted Stock Award Agreement, as the Board will determine in its sole discretion, so long as Common Stock awarded under the Restricted Stock Award
Agreement remains subject to the terms of the Restricted Stock Award Agreement. 
 (v) Dividends. A Restricted Stock Award
Agreement may provide that any dividends paid on Restricted Stock will be subject to the same vesting and forfeiture restrictions as apply to the shares subject to the Restricted Stock Award to which they relate. 

(b) Restricted Stock Unit Awards. Each Restricted Stock Unit Award Agreement will be in such form and will contain
such terms and conditions as the Board may deem appropriate. The terms and conditions of Restricted Stock Unit Award Agreements may change from time to time, and the terms and conditions of separate Restricted Stock Unit Award Agreements need not be
identical. Each Restricted Stock Unit Award Agreement will conform to (through incorporation of the provisions hereof by reference in the Agreement or otherwise) the substance of each of the following provisions: 

(i) Consideration. At the time of grant of a Restricted Stock Unit Award, the Board will determine the
consideration, if any, to be paid by the Participant upon delivery of each share of Common Stock subject to the Restricted Stock Unit Award. The consideration to be paid (if any) by the Participant for each share of Common Stock subject to a
Restricted Stock Unit Award may be paid in any form of legal consideration that may be acceptable to the Board, in its sole discretion, and permissible under applicable law. 

(ii) Vesting. At the time of the grant of a Restricted Stock Unit Award, the Board may impose such restrictions on or
conditions to the vesting of the Restricted Stock Unit Award as it, in its sole discretion, deems appropriate. 
 (iii)
Payment. A Restricted Stock Unit Award may be settled by the delivery of shares of Common Stock, their cash equivalent, any combination thereof or in any other form of consideration, as determined by the Board and contained in the
Restricted Stock Unit Award Agreement. 
 (iv) Additional Restrictions. At the time of the grant of a
Restricted Stock Unit Award, the Board, as it deems appropriate, may impose such restrictions or conditions that delay the delivery of the shares of Common Stock (or their cash equivalent) subject to a Restricted Stock Unit Award to a time after the
vesting of such Restricted Stock Unit Award. 

  
 10. 

 (v) Dividend Equivalents. Dividend equivalents may be credited in
respect of shares of Common Stock covered by a Restricted Stock Unit Award, as determined by the Board and contained in the Restricted Stock Unit Award Agreement. At the sole discretion of the Board, such dividend equivalents may be converted into
additional shares of Common Stock covered by the Restricted Stock Unit Award in such manner as determined by the Board. Any additional shares covered by the Restricted Stock Unit Award credited by reason of such dividend equivalents will be subject
to all of the same terms and conditions of the underlying Restricted Stock Unit Award Agreement to which they relate. 
 (vi)
Termination of Participant’s Continuous Service. Except as otherwise provided in the applicable Restricted Stock Unit Award Agreement, such portion of the Restricted Stock Unit Award that has not vested
will be forfeited upon the Participant’s termination of Continuous Service.  
 (vii) Compliance with
Section 409A of the Code. Notwithstanding anything to the contrary set forth herein, any Restricted Stock Unit Award granted under the Plan that is not exempt from the requirements of Section 409A of the Code shall
contain such provisions so that such Restricted Stock Unit Award will comply with the requirements of Section 409A of the Code. Such restrictions, if any, shall be determined by the Board and contained in the Restricted Stock Unit Award
Agreement evidencing such Restricted Stock Unit Award. For example, such restrictions may include, without limitation, a requirement that any Common Stock that is to be issued in a year following the year in which the Restricted Stock Unit Award
vests must be issued in accordance with a fixed pre-determined schedule. 
 (c) Other Stock
Awards. Other forms of Stock Awards valued in whole or in part by reference to, or otherwise based on, Common Stock, including the appreciation in value thereof (e.g., options or stock rights with an exercise price or strike price less than 100%
of the Fair Market Value of the Common Stock at the time of grant) may be granted either alone or in addition to Stock Awards provided for under Section 5 and the preceding provisions of this Section 6. Subject to the provisions of the
Plan, the Board will have sole and complete authority to determine the persons to whom and the time or times at which such Other Stock Awards will be granted, the number of shares of Common Stock (or the cash equivalent thereof) to be granted
pursuant to such Other Stock Awards and all other terms and conditions of such Other Stock Awards. 
  

	7.	 COVENANTS OF THE COMPANY.

 (a) Availability of Shares. The Company will keep available at all times the number of shares of
Common Stock reasonably required to satisfy then-outstanding Stock Awards. 
 (b) Securities Law Compliance. The Company will seek to
obtain from each regulatory commission or agency having jurisdiction over the Plan such authority as may be required to grant Stock Awards and to issue and sell shares of Common Stock upon exercise of the Stock Awards; provided, however, that
this undertaking will not require the Company to register under the Securities Act the Plan, any Stock Award or any Common Stock issued or issuable pursuant to any such Stock Award. If, after reasonable efforts and at a reasonable cost, the Company
is unable to obtain from any such regulatory commission or agency the authority that counsel for the Company deems necessary for the lawful issuance and sale of Common Stock under the Plan, the Company will be relieved from any liability for failure
to issue and sell Common Stock upon exercise of such Stock Awards unless and until such authority is obtained. A Participant will not be eligible for the grant of a Stock Award or the subsequent issuance of cash or Common Stock pursuant to the Stock
Award if such grant or issuance would be in violation of any applicable securities law. 

  
 11. 

 (c) No Obligation to Notify or Minimize Taxes. The Company will have no duty
or obligation to any Participant to advise such holder as to the time or manner of exercising such Stock Award. Furthermore, the Company will have no duty or obligation to warn or otherwise advise such holder of a pending termination or expiration
of a Stock Award or a possible period in which the Stock Award may not be exercised. The Company has no duty or obligation to minimize the tax consequences of a Stock Award to the holder of such Stock Award. 

 

	8.	 MISCELLANEOUS. 

(a) Use of Proceeds from Sales of Common Stock. Proceeds from the sale of shares of Common Stock pursuant to Stock Awards will
constitute general funds of the Company. 
 (b) Corporate Action Constituting Grant of Stock Awards. Corporate action constituting a
grant by the Company of a Stock Award to any Participant will be deemed completed as of the date of such corporate action, unless otherwise determined by the Board, regardless of when the instrument, certificate, or letter evidencing the Stock Award
is communicated to, or actually received or accepted by, the Participant. In the event that the corporate records (e.g., Board consents, resolutions or minutes) documenting the corporate action constituting the grant contain terms (e.g., exercise
price, vesting schedule or number of shares) that are inconsistent with those in the Stock Award Agreement or related grant documents as a result of a clerical error in the papering of the Stock Award Agreement or related grant documents, the
corporate records will control and the Participant will have no legally binding right to the incorrect term in the Stock Award Agreement or related grant documents. 

(c) Stockholder Rights. No Participant will be deemed to be the holder of, or to have any of the rights of a holder with respect to, any
shares of Common Stock subject to a Stock Award unless and until (i) such Participant has satisfied all requirements for exercise of, or the issuance of shares of Common Stock under, the Stock Award pursuant to its terms, and (ii) the
issuance of the Common Stock subject to the Stock Award has been entered into the books and records of the Company. 
 (d) No Employment
or Other Service Rights. Nothing in the Plan, any Stock Award Agreement or any other instrument executed thereunder or in connection with any Stock Award granted pursuant thereto will confer upon any Participant any right to continue to serve
the Company or an Affiliate in the capacity in effect at the time the Stock Award was granted or will affect the right of the Company or an Affiliate to terminate (i) the employment of an Employee with or without notice and with or without
cause, (ii) the service of a Consultant pursuant to the terms of such Consultant’s agreement with the Company or an Affiliate, or (iii) the service of a Director pursuant to the bylaws of the Company or an Affiliate, and any
applicable provisions of the corporate law of the state in which the Company or the Affiliate is incorporated, as the case may be. 
 (e)
Change in Time Commitment. In the event a Participant’s regular level of time commitment in the performance of his or her services for the Company and any Affiliates is reduced (for example, and without limitation, if the Participant is an
Employee of the Company and the Employee has a change in status from a full-time Employee to a part-time Employee or takes an extended leave of absence) after the date of grant of any Stock Award to the Participant, the Board has the right in its
sole discretion to (x) make a corresponding reduction in the number of shares subject to any portion of such Stock Award that is scheduled to vest or become payable after the date of such change in time commitment, and (y) in lieu of or in
combination with such a reduction, extend the vesting or payment schedule applicable to such Stock Award. In the event of any such reduction, the Participant will have no right with respect to any portion of the Stock Award that is so reduced or
extended. 

  
 12. 

 (f) Incentive Stock Option Limitations. To the extent that the aggregate Fair Market
Value (determined at the time of grant) of Common Stock with respect to which Incentive Stock Options are exercisable for the first time by any Optionholder during any calendar year (under all plans of the Company and any Affiliates) exceeds
$100,000 (or such other limit established in the Code) or otherwise does not comply with the rules governing Incentive Stock Options, the Options or portions thereof that exceed such limit (according to the order in which they were granted) or
otherwise do not comply with such rules will be treated as Nonstatutory Stock Options, notwithstanding any contrary provision of the applicable Option Agreement(s). 

(g) Execution of Additional Documents. As a condition to accepting a Stock Award under the Plan, the Participant agrees to execute any
additional documents or instruments necessary or desirable, as determined in the Company’s sole discretion, to carry out the purposes or intent of the Stock Award, or facilitate compliance with securities and/or other regulatory requirements,
in each case at the Company’s request. 
 (h) Investment Assurances. The Company may require a Participant, as a condition of
exercising or acquiring Common Stock under any Stock Award, (i) to give written assurances satisfactory to the Company as to the Participant’s knowledge and experience in financial and business matters and/or to employ a purchaser
representative reasonably satisfactory to the Company who is knowledgeable and experienced in financial and business matters and that the Participant is capable of evaluating, alone or together with the purchaser representative, the merits and risks
of exercising the Stock Award; and (ii) to give written assurances satisfactory to the Company stating that the Participant is acquiring Common Stock subject to the Stock Award for the Participant’s own account and not with any present
intention of selling or otherwise distributing the Common Stock. The foregoing requirements, and any assurances given pursuant to such requirements, will be inoperative if (A) the issuance of the shares upon the exercise or acquisition of
Common Stock under the Stock Award has been registered under a then currently effective registration statement under the Securities Act, or (B) as to any particular requirement, a determination is made by counsel for the Company that such
requirement need not be met in the circumstances under the then applicable securities laws. The Company may, upon advice of counsel to the Company, place legends on stock certificates issued under the Plan as such counsel deems necessary or
appropriate in order to comply with applicable securities laws, including, but not limited to, legends restricting the transfer of the Common Stock. 

(i) Withholding Obligations. Unless prohibited by the terms of a Stock Award Agreement, the Company may, in its
sole discretion, satisfy any federal, state or local tax withholding obligation relating to a Stock Award by any of the following means or by a combination of such means: (i) causing the Participant to tender a cash payment;
(ii) withholding shares of Common Stock from the shares of Common Stock issued or otherwise issuable to the Participant in connection with the Stock Award; provided, however, that no shares of Common Stock are withheld with a value
exceeding the minimum amount of tax required to be withheld by law (or such lesser amount as may be necessary to avoid classification of the Stock Award as a liability for financial accounting purposes); (iii) withholding cash from a Stock
Award settled in cash; (iv) withholding payment from any amounts otherwise payable to the Participant; or (v) by such other method as may be set forth in the Stock Award Agreement. 

  
 13. 

 (j) Electronic Delivery. Any reference herein to a “written” agreement or
document will include any agreement or document delivered electronically or posted on the Company’s intranet (or other shared electronic medium controlled by the Company to which the Participant has access). 

(k) Deferrals. To the extent permitted by applicable law, the Board, in its sole discretion, may determine that the delivery of Common
Stock or the payment of cash, upon the exercise, vesting or settlement of all or a portion of any Stock Award may be deferred and may establish programs and procedures for deferral elections to be made by Participants. Deferrals by Participants will
be made in accordance with Section 409A of the Code. Consistent with Section 409A of the Code, the Board may provide for distributions while a Participant is still an employee or otherwise providing services to the Company. The Board is
authorized to make deferrals of Stock Awards and determine when, and in what annual percentages, Participants may receive payments, including lump sum payments, following the Participant’s termination of Continuous Service, and implement such
other terms and conditions consistent with the provisions of the Plan and in accordance with applicable law. 
 (l) Compliance with
Section 409A of the Code. To the extent that the Board determines that any Stock Award granted hereunder is subject to Section 409A of the Code, the Stock Award Agreement evidencing such Stock Award shall
incorporate the terms and conditions necessary to avoid the consequences specified in Section 409A(a)(1) of the Code. To the extent applicable, the Plan and Stock Award Agreements shall be interpreted in accordance with Section 409A of the
Code. Notwithstanding anything to the contrary in the Plan (and unless the Stock Award Agreement specifically provides otherwise), if the shares of Common Stock are publicly traded, and if a Participant holding a Stock Award that constitutes
“deferred compensation” under Section 409A of the Code is a “specified employee” for purposes of Section 409A of the Code, no distribution or payment of any amount that is due because of a “separation from
service” (as defined in Section 409A of the Code without regard to alternative definitions thereunder) will be issued or paid before the date that is six months following the date of such Participant’s “separation from
service” (as defined in Section 409A of the Code without regard to alternative definitions thereunder) or, if earlier, the date of the Participant’s death, unless such distribution or payment can be made in a manner that complies with
Section 409A of the Code, and any amounts so deferred will be paid in a lump sum on the day after such six month period elapses, with the balance paid thereafter on the original schedule. 

(m) Repurchase Limitation. The terms of any repurchase right will be specified in the Stock Award Agreement. The repurchase price
for vested shares of Common Stock will be the Fair Market Value of the shares of Common Stock on the date of repurchase. The repurchase price for unvested shares of Common Stock will be the lower of (i) the Fair Market Value of the shares of
Common Stock on the date of repurchase or (ii) their original purchase price. However, the Company will not exercise its repurchase right until at least six months (or such longer or shorter period of time necessary to avoid classification
of the Stock Award as a liability for financial accounting purposes) have elapsed following delivery of shares of Common Stock subject to the Stock Award, unless otherwise specifically provided by the Board. 

 

	9.	 ADJUSTMENTS UPON CHANGES IN
COMMON STOCK; OTHER CORPORATE EVENTS. 

(a) Capitalization Adjustments. In the event of a Capitalization Adjustment, the Board will appropriately and proportionately
adjust: (i) the class(es) and maximum number of securities subject to the Plan pursuant to Section 3(a), (ii) the class(es) and maximum number of securities that may be issued pursuant to the exercise of Incentive Stock Options
pursuant to Section 3(c), and (iii) the class(es) and number of securities and price per share of stock subject to outstanding Stock Awards. The Board will make such adjustments, and its determination will be final, binding and conclusive.

  
 14. 

 (b) Dissolution or Liquidation. Except as otherwise provided in the Stock Award
Agreement, in the event of a dissolution or liquidation of the Company, all outstanding Stock Awards (other than Stock Awards consisting of vested and outstanding shares of Common Stock not subject to a forfeiture condition or the Company’s
right of repurchase) will terminate immediately prior to the completion of such dissolution or liquidation, and the shares of Common Stock subject to the Company’s repurchase rights or subject to a forfeiture condition may be repurchased or
reacquired by the Company notwithstanding the fact that the holder of such Stock Award is providing Continuous Service, provided, however, that the Board may, in its sole discretion, cause some or all Stock Awards to become fully vested,
exercisable and/or no longer subject to repurchase or forfeiture (to the extent such Stock Awards have not previously expired or terminated) before the dissolution or liquidation is completed but contingent on its completion. 

(c) Corporate Transaction. The following provisions will apply to Stock Awards in the event of a Corporate Transaction unless
otherwise provided in the instrument evidencing the Stock Award or any other written agreement between the Company or any Affiliate and the Participant or unless otherwise expressly provided by the Board at the time of grant of a Stock Award. In the
event of a Corporate Transaction, then, notwithstanding any other provision of the Plan, the Board may take one or more of the following actions with respect to Stock Awards, contingent upon the closing or completion of the Corporate Transaction:

 (i) arrange for the surviving corporation or acquiring corporation (or the surviving or acquiring corporation’s parent
company) to assume or continue the Stock Award or to substitute a similar stock award for the Stock Award (including, but not limited to, an award to acquire the same consideration paid to the stockholders of the Company pursuant to the Corporate
Transaction); 
 (ii) arrange for the assignment of any reacquisition or repurchase rights held by the Company in respect of Common
Stock issued pursuant to the Stock Award to the surviving corporation or acquiring corporation (or the surviving or acquiring corporation’s parent company); 

(iii) accelerate the vesting, in whole or in part, of the Stock Award (and, if applicable, the time at which the Stock Award may be
exercised) to a date prior to the effective time of such Corporate Transaction as the Board determines (or, if the Board does not determine such a date, to the date that is five days prior to the effective date of the Corporate Transaction),
with such Stock Award terminating if not exercised (if applicable) at or prior to the effective time of the Corporate Transaction; provided, however, that the Board may require Participants to complete and deliver to the Company a notice of
exercise before the effective date of a Corporate Transaction, which exercise is contingent upon the effectiveness of such Corporate Transaction; 

(iv) arrange for the lapse, in whole or in part, of any reacquisition or repurchase rights held by the Company with respect to the Stock
Award; 
 (v) cancel or arrange for the cancellation of the Stock Award, to the extent not vested or not exercised prior to the
effective time of the Corporate Transaction, in exchange for such cash consideration (including no consideration) as the Board, in its sole discretion, may consider appropriate; and 

(vi) make a payment, in such form as may be determined by the Board equal to the excess, if any, of (A) the value of the property
the Participant would have received upon the exercise of the Stock Award immediately prior to the effective time of the Corporate Transaction, over (B) any exercise price payable by such holder in connection with such exercise. For clarity,
this payment may be zero ($0) 

  
 15. 

 
if the value of the property is equal to or less than the exercise price. Payments under this provision may be delayed to the same extent that payment of consideration to the holders of the
Company’s Common Stock in connection with the Corporate Transaction is delayed as a result of escrows, earn outs, holdbacks or any other contingencies. 

The Board need not take the same action or actions with respect to all Stock Awards or portions thereof or with respect to all Participants. The Board may take
different actions with respect to the vested and unvested portions of a Stock Award.  
 (d) Change in Control. A Stock Award
may be subject to additional acceleration of vesting and exercisability upon or after a Change in Control as may be provided in the Stock Award Agreement for such Stock Award or as may be provided in any other written agreement between the Company
or any Affiliate and the Participant, but in the absence of such provision, no such acceleration will occur. 
 (e) Appointment of
Stockholder Representative. As a condition to the receipt of a Stock Award under this Plan, a Participant will be deemed to have agreed that the Stock Award will be subject to the terms of any agreement governing a Corporate Transaction
involving the Company, including, without limitation, a provision for the appointment of a shareholder representative that is authorized to act on the Participant’s behalf with respect to any escrow or other contingent consideration. 

(f) No Restriction on Right to Undertake Transactions. The grant of any Stock Award under the Plan and the issuance of shares pursuant
to any Stock Award does not affect or restrict in any way the right or power of the Company or the stockholders of the Company to make or authorize any adjustment, recapitalization, reorganization or other change in the Company’s capital
structure or its business, any merger or consolidation of the Company, any issue of stock or of options, Options or rights to purchase stock or of bonds, debentures, preferred or prior preference stocks whose rights are superior to or affect the
Common Stock or the rights thereof or which are convertible into or exchangeable for Common Stock, or the dissolution or liquidation of the Company, or any sale or transfer of all or any part of its assets or business, or any other corporate act or
proceeding, whether of a similar character or otherwise. 
  

	10.	 PLAN TERM; EARLIER TERMINATION OR
SUSPENSION OF THE PLAN. 

 (a) Plan Term. The Board
may suspend or terminate the Plan at any time. Unless terminated sooner by the Board, the Plan will automatically terminate on the day before the 10th anniversary of the earlier of (i) the date the Plan is adopted by the Board, or (ii) the
date the Plan is approved by the stockholders of the Company. No Stock Awards may be granted under the Plan while the Plan is suspended or after it is terminated. 

(b) No Impairment of Rights. Suspension or termination of the Plan will not impair rights and obligations under any Stock Award granted
while the Plan is in effect except with the written consent of the affected Participant or as otherwise permitted in the Plan. 
  

	11.	 EFFECTIVE DATE OF PLAN.

 This Plan will become effective on the Effective Date.  

 

	12.	 CHOICE OF LAW. 

The laws of the State of Delaware will govern all questions concerning the construction, validity and interpretation of this Plan,
without regard to that state’s conflict of laws rules. 

  
 16. 

 13. DEFINITIONS. As used in the Plan, the following
definitions will apply to the capitalized terms indicated below: 
 (a) “Affiliate” means, at the time of
determination, any “parent” or “majority-owned subsidiary” of the Company, as such terms are defined in Rule 405. The Board will have the authority to determine the time or times at which “parent” or
“majority-owned subsidiary” status is determined within the foregoing definition. 
 (b) “Board”
means the Board of Directors of the Company. 
 (c) “Capitalization Adjustment” means any change that is made
in, or other events that occur with respect to, the Common Stock subject to the Plan or subject to any Stock Award after the Effective Date without the receipt of consideration by the Company through merger, consolidation, reorganization,
recapitalization, reincorporation, stock dividend, dividend in property other than cash, large nonrecurring cash dividend, stock split, reverse stock split, liquidating dividend, combination of shares, exchange of shares, change in corporate
structure, or any similar equity restructuring transaction, as that term is used in Statement of Financial Accounting Standards Board Accounting Standards Codification Topic 718 (or any successor thereto). Notwithstanding the foregoing, the
conversion of any convertible securities of the Company will not be treated as a Capitalization Adjustment. 
 (d)
“Cause” will have the meaning ascribed to such term in any written agreement between the Participant and the Company defining such term and, in the absence of such agreement, such term means, with respect to
a Participant, the occurrence of any of the following events: (i) such Participant’s commission of any felony or any crime involving fraud, dishonesty or moral turpitude under the laws of the United States or any state thereof;
(ii) such Participant’s attempted commission of, or participation in, a fraud or act of dishonesty against the Company; (iii) such Participant’s intentional, material violation of any contract or agreement between the Participant
and the Company or of any statutory duty owed to the Company; (iv) such Participant’s unauthorized use or disclosure of the Company’s confidential information or trade secrets; or (v) such Participant’s gross misconduct. The
determination that a termination of the Participant’s Continuous Service is either for Cause or without Cause will be made by the Company, in its sole discretion. Any determination by the Company that the Continuous Service of a Participant was
terminated with or without Cause for the purposes of outstanding Stock Awards held by such Participant will have no effect upon any determination of the rights or obligations of the Company or such Participant for any other purpose. 

(e) “Change in Control” means the occurrence, in a single transaction or in a series of related transactions, of
any one or more of the following events: 
 (i) any Exchange Act Person becomes the Owner, directly or indirectly, of securities of
the Company representing more than 50% of the combined voting power of the Company’s then outstanding securities other than by virtue of a merger, consolidation or similar transaction. Notwithstanding the foregoing, a Change in Control will not
be deemed to occur (A) on account of the acquisition of securities of the Company directly from the Company, (B) on account of the acquisition of securities of the Company by an investor, any affiliate thereof or any other Exchange Act
Person that acquires the Company’s securities in a transaction or series of related transactions the primary purpose of which is to obtain financing for the Company through the issuance of equity securities or (C) solely because the level
of Ownership held by any Exchange Act Person (the “Subject Person”) exceeds the designated percentage threshold of the outstanding voting securities as a result of a repurchase or other
acquisition of voting securities by the Company reducing the number of shares outstanding, provided that if a Change in 

  
 17. 

 
Control would occur (but for the operation of this sentence) as a result of the acquisition of voting securities by the Company, and after such share acquisition, the Subject Person becomes the
Owner of any additional voting securities that, assuming the repurchase or other acquisition had not occurred, increases the percentage of the then outstanding voting securities Owned by the Subject Person over the designated percentage threshold,
then a Change in Control will be deemed to occur;  
 (ii) there is consummated a merger, consolidation or similar transaction
involving (directly or indirectly) the Company and, immediately after the consummation of such merger, consolidation or similar transaction, the stockholders of the Company immediately prior thereto do not Own, directly or indirectly, either
(A) outstanding voting securities representing more than 50% of the combined outstanding voting power of the surviving Entity in such merger, consolidation or similar transaction or (B) more than 50% of the combined outstanding voting
power of the parent of the surviving Entity in such merger, consolidation or similar transaction, in each case in substantially the same proportions as their Ownership of the outstanding voting securities of the Company immediately prior to such
transaction; or 
 (iii) there is consummated a sale, lease, exclusive license or other disposition of all or substantially all of the
consolidated assets of the Company and its Subsidiaries, other than a sale, lease, license or other disposition of all or substantially all of the consolidated assets of the Company and its Subsidiaries to an Entity, more than 50% of the combined
voting power of the voting securities of which are Owned by stockholders of the Company in substantially the same proportions as their Ownership of the outstanding voting securities of the Company immediately prior to such sale, lease, license or
other disposition. 
 Notwithstanding the foregoing definition or any other provision of this Plan, (A) the term Change in Control will not include a
sale of assets, merger or other transaction effected exclusively for the purpose of changing the domicile of the Company, and (B) the definition of Change in Control (or any analogous term) in an individual written agreement between the Company
or any Affiliate and the Participant will supersede the foregoing definition with respect to Stock Awards subject to such agreement; provided, however, that if no definition of Change in Control or any analogous term is set forth in such an
individual written agreement, the foregoing definition will apply. 
 (f) “Code” means the Internal Revenue
Code of 1986, as amended, including any applicable regulations and guidance thereunder. 
 (g) “Committee”
means a committee of one or more Directors to whom authority has been delegated by the Board in accordance with Section 2(c). 
 (h)
“Common Stock” means the common stock of the Company. 
 (i) “Company” means 1Life
Healthcare, Inc., a Delaware corporation. 
 (j) “Consultant” means any person, including an advisor, who is
(i) engaged by the Company or an Affiliate to render consulting or advisory services and is compensated for such services, or (ii) serving as a member of the board of directors of an Affiliate and is compensated for such services. However,
service solely as a Director, or payment of a fee for such service, will not cause a Director to be considered a “Consultant” for purposes of the Plan.  

  
 18. 

 (k) “Continuous Service” means that the Participant’s
service with the Company or an Affiliate, whether as an Employee, Director or Consultant, is not interrupted or terminated. A change in the capacity in which the Participant renders service to the Company or an Affiliate as an Employee, Director or
Consultant or a change in the Entity for which the Participant renders such service, provided that there is no interruption or termination of the Participant’s service with the Company or an Affiliate, will not terminate a Participant’s
Continuous Service; provided, however, that if the Entity for which a Participant is rendering services ceases to qualify as an Affiliate, as determined by the Board in its sole discretion, such Participant’s Continuous Service will be
considered to have terminated on the date such Entity ceases to qualify as an Affiliate. For example, a change in status from an Employee of the Company to a Consultant of an Affiliate or to a Director will not constitute an interruption of
Continuous Service. To the extent permitted by law, the Board or the chief executive officer of the Company, in that party’s sole discretion, may determine whether Continuous Service will be considered interrupted in the case of (i) any
leave of absence approved by the Board or chief executive officer, including sick leave, military leave or any other personal leave, or (ii) transfers between the Company, an Affiliate, or their successors. Notwithstanding the foregoing, a
leave of absence will be treated as Continuous Service for purposes of vesting in a Stock Award only to such extent as may be provided in the Company’s leave of absence policy, in the written terms of any leave of absence agreement or policy
applicable to the Participant, or as otherwise required by law. 
 (l) “Corporate Transaction” means the
consummation, in a single transaction or in a series of related transactions, of any one or more of the following events: 
 (i) a
sale or other disposition of all or substantially all, as determined by the Board in its sole discretion, of the consolidated assets of the Company and its Subsidiaries; 

(ii) a sale or other disposition of more than 50% of the outstanding securities of the Company; 

(iii) a merger, consolidation or similar transaction following which the Company is not the surviving corporation; or 

(iv) a merger, consolidation or similar transaction following which the Company is the surviving corporation but the shares of Common
Stock outstanding immediately preceding the merger, consolidation or similar transaction are converted or exchanged by virtue of the merger, consolidation or similar transaction into other property, whether in the form of securities, cash or
otherwise. 
 (m) “Director” means a member of the Board. 

(n) “Disability” means, with respect to a Participant, the inability of such Participant to engage in any
substantial gainful activity by reason of any medically determinable physical or mental impairment that can be expected to result in death or that has lasted or can be expected to last for a continuous period of not less than
twelve (12) months as provided in Sections 22(e)(3) and 409A(a)(2)(c)(i) of the Code, and will be determined by the Board on the basis of such medical evidence as the Board deems warranted under the circumstances. 

(o) “Effective Date” means the effective date of this Plan, which is February 9, 2017, the date this
Plan is adopted by the Board. 

  
 19. 

 (p) “Employee” means any person employed by the Company or an
Affiliate. However, service solely as a Director, or payment of a fee for such services, will not cause a Director to be considered an “Employee” for purposes of the Plan. 

(q) “Entity” means a corporation, partnership, limited liability company or other entity. 

(r) “Exchange Act” means the Securities Exchange Act of 1934, as amended, and the rules and regulations
promulgated thereunder. 
 (s) “Exchange Act Person” means any natural person, Entity or
“group” (within the meaning of Section 13(d) or 14(d) of the Exchange Act), except that “Exchange Act Person” will not include (i) the Company or any Subsidiary of the Company, (ii) any employee benefit
plan of the Company or any Subsidiary of the Company or any trustee or other fiduciary holding securities under an employee benefit plan of the Company or any Subsidiary of the Company, (iii) an underwriter temporarily holding securities
pursuant to a registered public offering of such securities, (iv) an Entity Owned, directly or indirectly, by the stockholders of the Company in substantially the same proportions as their Ownership of stock of the Company; or (v) any
natural person, Entity or “group” (within the meaning of Section 13(d) or 14(d) of the Exchange Act) that, as of the Effective Date, is the Owner, directly or indirectly, of securities of the Company representing more than 50% of the
combined voting power of the Company’s then outstanding securities. 
 (t) “Fair Market Value” means, as
of any date, the value of the Common Stock determined by the Board in compliance with Section 409A of the Code or, in the case of an Incentive Stock Option, in compliance with Section 422 of the Code. 

(u) “Incentive Stock Option” means an option granted pursuant to Section 5 of the Plan that is intended to
be, and that qualifies as, an “incentive stock option” within the meaning of Section 422 of the Code. 
 (v)
“Nonstatutory Stock Option” means an option granted pursuant to Section 5 of the Plan that does not qualify as an Incentive Stock Option. 

(w) “Officer” means any person designated by the Company as an officer. 

(x) “Option” means an Incentive Stock Option or a Nonstatutory Stock Option to purchase shares of Common Stock
granted pursuant to the Plan. 
 (y) “Option Agreement” means a written agreement between the Company and an
Optionholder evidencing the terms and conditions of an Option grant. Each Option Agreement will be subject to the terms and conditions of the Plan. 

(z) “Optionholder” means a person to whom an Option is granted pursuant to the Plan or, if applicable, such
other person who holds an outstanding Option. 
 (aa) “Other Stock Award” means an award based
in whole or in part by reference to the Common Stock which is granted pursuant to the terms and conditions of Section 6(c). 

(bb) “Other Stock Award Agreement” means a written agreement between the Company and a holder of
an Other Stock Award evidencing the terms and conditions of an Other Stock Award grant. Each Other Stock Award Agreement will be subject to the terms and conditions of the Plan. 

  
 20. 

 (cc) “Own,” “Owned,”
“Owner,” “Ownership” A person or Entity will be deemed to “Own,” to have “Owned,” to be the “Owner” of, or to have acquired “Ownership” of securities if
such person or Entity, directly or indirectly, through any contract, arrangement, understanding, relationship or otherwise, has or shares voting power, which includes the power to vote or to direct the voting, with respect to such securities. 

(dd) “Participant” means a person to whom a Stock Award is granted pursuant to the Plan or, if applicable, such
other person who holds an outstanding Stock Award. 
 (ee) “Plan” means this 2017 Equity Incentive Plan. 

(ff) “Restricted Stock Award” means an award of shares of Common Stock which is granted pursuant to the terms
and conditions of Section 6(a). 
 (gg) “Restricted Stock Award Agreement” means a written agreement
between the Company and a holder of a Restricted Stock Award evidencing the terms and conditions of a Restricted Stock Award grant. Each Restricted Stock Award Agreement will be subject to the terms and conditions of the Plan. 

(hh) “Restricted Stock Unit Award” means a right to receive shares of Common Stock which is
granted pursuant to the terms and conditions of Section 6(b). 
 (ii) “Restricted Stock Unit Award
Agreement” means a written agreement between the Company and a holder of a Restricted Stock Unit Award evidencing the terms and conditions of a Restricted Stock Unit Award grant. Each Restricted Stock Unit Award Agreement
will be subject to the terms and conditions of the Plan. 
 (jj) “Rule 405” means Rule 405 promulgated under
the Securities Act. 
 (kk) “Rule 701” means Rule 701 promulgated under the Securities Act. 

(ll) “Securities Act” means the Securities Act of 1933, as amended. 

(mm) “Stock Appreciation Right” or “SAR” means a right to receive the appreciation on
Common Stock that is granted pursuant to the terms and conditions of Section 5. 
 (nn) “Stock Appreciation Right
Agreement” means a written agreement between the Company and a holder of a Stock Appreciation Right evidencing the terms and conditions of a Stock Appreciation Right grant. Each Stock Appreciation Right Agreement will be subject to the
terms and conditions of the Plan. 
 (oo) “Stock Award” means any right to receive Common Stock granted under
the Plan, including an Incentive Stock Option, a Nonstatutory Stock Option, a Restricted Stock Award, a Restricted Stock Unit Award, a Stock Appreciation Right or any Other Stock Award. 

(pp) “Stock Award Agreement” means a written agreement between the Company and a Participant evidencing the
terms and conditions of a Stock Award grant. Each Stock Award Agreement will be subject to the terms and conditions of the Plan. 

  
 21. 

 (qq) “Subsidiary” means, with respect to the Company,
(i) any corporation of which more than 50% of the outstanding capital stock having ordinary voting power to elect a majority of the board of directors of such corporation (irrespective of whether, at the time, stock of any other class or
classes of such corporation will have or might have voting power by reason of the happening of any contingency) is at the time, directly or indirectly, Owned by the Company, and (ii) any partnership, limited liability company or other entity in
which the Company has a direct or indirect interest (whether in the form of voting or participation in profits or capital contribution) of more than 50%. 

(rr) “Ten Percent Stockholder” means a person who Owns (or is deemed to Own pursuant to Section 424(d) of
the Code) stock possessing more than 10% of the total combined voting power of all classes of stock of the Company or any Affiliate. 

  
 22.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00303-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00303-of-00352.parquet"}]]